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Introduction to the study
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Introduction
Patients with end stage renal failure generally have anemia. This anemia has a
great impact on physical capacity, general well being and cognitive and sexual
functions, thus limiting the quality of life. Before the wide therapeutical appli-
cation of erythropoietin, more than 50% of those patients needed periodically
red cell transfusions for relieving the symptoms of anemia [1]. However, a
transfusion gives relieve for a short period only and has certain risks such as
transmission of infections, iron overload, the induction of lymfocytotoxic anti-
bodies and erythroid suppression [2]. Therefore, therapeutical alternatives for
correcting this anemia were imperative. Attempts with androgens and cobalt and
optimal ization of dialysis procedures were either not effective enough or created
inacceptabte side effects.
The anemia of chronic renal failure
The association between anemia with chronic renal disease and renal failure has
been described for the first time by Richard Bright in 1836. It is a normocytic
and normochromic anemia with a hypoproliferative bone marrow. The mechan-
isms responsible for the anemia of renal disease are: (1) decreased marrow
stimulation, (2) decreased marrow response, and (3) decreased red cell survival.
(1) Decreased marrow stimulation
Decreased marrow stimulation is the most important cause of anemia in renal
disease. Erythropoietin (Epo), which stimulates marrow red cell production, is
produced by the peritubular capillary endothelial cells and interstitial fibroblasts
of the kidney [3-4]. Its production depends on the availability of oxygen to the
kidney and the registration by a not yet defined oxygen sensoring mechanism in
the kidney itself [5].
Renal insufficiency is leading to a decreased erythropoietin production,
blunting the normal feedback between erythropoiesis and erythropoietin pro-
duction. There are other factors as well that blunt the response of the marrow to
Epo in uremics, such as altered oxygen sensoring [6], the increase in red cell 2,
3-DPG levels with a right shift on the hemoglobin - oxygen dissociation curve
and subsequently increased oxygen delivery to the oxygen sensor [7], direct
inhibition of the erythropoietin immunoreactivity [8] and retention of inhibitors
of erythropoietin.
(2) Decreased marrow response
A decreased marrow response for erythropoietin might be due to the presence
of uremic inhibitors [9-10]: candidates are polyamines [11], parathyroid hor-
mone [12], ribonuclease [13] and prostaglandins [14].
Several other factors can give a decreased response such as iron deficiency,
decreased iron utilization due to inflammatory iron block [15], aluminium
toxicity [16], folate deficiency [17], and secondary hyperparathyroidism [18].
(3) Decreased red cell survival
The decrease of red cell survival during renal failure and dialysis is due to blood
loss by frequent venapunctures, to blood loss associated with the dialysis
procedure itself and surgery. The latter is amplificated by the increased uremic
bleeding tendency. A decreased red cell survival may also be due to intravascu-
lar hemolysis of dysfunctioning red cells in the uremic environment as well as
hemolysis secondary to improper dialysis techniques, resulting in oncotic,
thermal and mechanical injury of the red cells.
History and development of erythropoietin
In 1906, Paul Carnot hypothesized that erythropoiesis was regulated by humoral
factors [19]. Jacobson detected the central role of the kidney in erythropoiesis
[20]. Erythropoietin was extracted and purified by Goldwasser and coworkers
from the plasma of uremic sheep [21-23]. Many years later, it was demonstrated
that erythropoietin rich plasma of uremic sheep could correct renal anemia of
uremic sheep [24]. From that moment on it was attempted to purify erythro-
poietin from the urine of anemic patients. For this purification, huge amounts of
urine were necessary to obtain small amounts of erythropoietin.
The amino-acid sequence of erythropoietin was partially determined by
Miyake et al [25] and the cloning of the gene coding for human erythropoietin
successfully undertaken by Jacobs et al [26] and Lin et al [27].
Since the successful insertion of the gene for human erythropoietin in a
mammalial cell line, large amounts of recombinant human erythropoietin (Re-
HuEpo) became widely available for therapeutical application.
Treatment with recombinant human erythropoietin for renal anemia
Beneficial effects
ReHuEpo corrects anemia in patients with end stage renal disease and in patients
maintained on dialysis [28-32]. A dose dependent increase in hemoglobin
concentration and an improved well being and physical fitness of the patients
were found [33-38]. Treatment with ReHuEpo ameliorated exercise capacity
and endurance. The duration of exercise, the maximum oxygen consumption,
oxygen uptake and anaerobic threshold improved [35, 39]. Analysis of pulmon-
ary function tests and ergospirometry demonstrated that improved oxygen
transport in the blood and changes of the anaerobic threshold and heart rate
appeared to be main causes of improvement. Respiratory mechanisms and gas
exchange remained unaltered [39].
Also, muscle energy metabolism, i.e. the rate of recovery of phosphocreatinin
as a function of oxydative phosphorylation, improved during treatment with
ReHuEpo [40].
Furthermore, improvements have been reported in brain and cognitive func-
tion [41-44], as well as in endocrine and sexual function [45-46], protein
metabolism [47-48] and primary hemostasis [49-50].
During treatment with ReHuEpo for renal anemia, side effects have been
encountered of which the clinical most important are:
(1) Hypertension.
If hypertension develops it occurs mainly during the induction phase of treat-
ment with ReHuEpo when the red cell mass increases [29-30, 32, 51-54],
especially in case of preexistent hypertension [51 ] and in case of a steep increase
of hematocrit.
When hematocrit rises, vasodilation due to hypoxia decreases, and the re-
sponsivity of the peripheral vascular smooth muscle cells to vasoconstrictor
stimuli might recover [55]. Furthermore, due to the elevated red blood cell mass,
blood viscosity will increase. All these factors may lead to an increase of blood
pressure. Patients with hypertension have a diminished compliance of the
vascular bed due to structural as well as functional changes [56-57], and
treatment with ReHuEpo might result in an exaggerated rise in peripheral
vascular resistance. Other factors, which could play a role, are an inadequate
reduction of the elevated cardiac output of chronic anemia [57-63], but also an
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incorrect estimation of dialysis dry weight. When dialysis dry weight is incor-
rectly estimated, volume contraction as well as fluid overload might lead to an
increase of blood pressure.
(2) Seizures
Seizures occur in about 4% of the patients treated with ReHuepo [28-29, 32].
These seizures might be caused by a critical reduction in cerebral perfusion
during treatment with ReHuEpo, by thrombo-embolism or by development of
hypertension.
(3) Clotting
An increased incidence of clotting of the vascular access [30, 32, 53,64-66) but
also of other vasculature has been reported during ReHuEpo therapy. This
clotting tendency can be explained by an increased blood viscosity, changes in
the hemostatic as well as in the fibrinolytic system but also hemodynamic
factors may contribute, especially in case of preexistent vasculopathy.
Hemodynamic response to chronic anemia
In patients with chronic anemia a hyperkinetic circulation is observed, charac-
terized by a high cardiac output. Furthermore, tissue extraction of oxygen is
increased [58-59]. This hyperkinetic circulation is caused by several factors.
Blood viscosity is reduced leading to a decrease of the resistance to blood flow
in the peripheral vessels, while the venous return is increased and thereby
cardiac output [67-68]. A diminished transport of oxygen causes vasodilatation
of the small vessels, leading to an increase of venous return and cardiac output.
The decreased arterial pressure in chronic anemia is related to a generalized
vasodilatation of the arterial system, whereas on the other hand venoconstriction
will maintain central blood volume and venous pressure [58]. So, one of the
major effects of anemia is a greatly increased workload on the heart with an
increase of myocardial oxygen consumption [69].
In anemic hemodialysis patients, stroke work index as well as left ventricular
work indices are increased [69]. Left ventricular end-diastolic pressure is
generally elevated. Myocardial mass is increased and will result in an increased
myocardial oxygen demand. When those oxygen requirements are not met
because of the reduced erythrocyte mass, myocardial failure could ensue.
Chronic anemia not only induces functional changes of the cardiovascular
system, but structural changes as well. The increased venous return will lead to
increased left ventricular dimensions, especially of the end diastolic left
ventricular diameter [70]. Furthermore, there is a significant relation between
anemia and left ventricular hypertrophy, indicating that anemia contributes to
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the development of left ventricular hypertrophy in patients with end stage renal
disease [71]. Moreover, Florenzano et al found some evidence for the existence
of a non-catecholamine positive inotropic factor in the serum of chronic anemic
patients [72]. It is likely that the development of hypertrophy allows tissue
oxygen needs to be met by increasing stroke volume, while normalizing systolic
wall stress.
Microvascular changes have been described in skin biopsies of hemodialysis
patients, such as thickening of the basement membrane, endothelial activation
and chronic inflammatory cell infiltration with participation of mast cells [73-
75]. Intravital microscopy of the finger nailfold of hypertensive dialysis patients
revealed a reduction of the number of capillaries and an increased percentage of
abnormal tortuous capillaries as compared to non-hypertensive dialysis patients
and controls.
The cause of the observed pathological microvascularity in hemodialysis
patients seems to be multifactorial: hypertension, uremic toxins and anemia may
all be responsible. After successful kidney transplantation complete normalisa-
tion of the microcirculation has been observed [75].
Hemodynamic effects of the correction of anemia by blood transfusion
The effect of a gradual correction of chronic anemia was studied by Duke et al
[58]. Significant decreases in heart rate, stroke index and cardiac index and an
increase in systemic vascular resistance were the most significant findings,
while rapid red blood cell transfusions resulted in a rise of cardiac output, venous
pressure and blood volume [76]. Neff et al [77] studied the hemodynamic effects
of serial red blood cell transfusion before and during a 6-12 week treatment
period. Cardiac index decreased, reaching a normal level at a hematocrit of 30%.
Diastolic blood pressure rose progressively (± 20 mmHg) and the vascular
resistance increased by 80%, when the hematocrit increased from 20 to 40%. An
inverse correlation between cardiac index and hematocrit (r=-0.76; p<0.01) and
a positive correlation between peripheral vascular resistance and hematocrit
(r=0.675; p<0.01) was observed.
Hematocrit is an important determinant of blood viscosity. The increasing
cardiac output, when hematocrit decreases, is related to an increase in venous
return and a decrease in outflow impedance. Murray et al [67] studied the effects
of changes in whole blood viscosity on hemodynamic responses in acute nor-
movolemic anemia, plotting mean cardiac output against mean hematocrit ratios
obtained during control periods and after isovolemic exchange with dextran
solutions of three different molecular weights. It turned out that recipients of low
molecular weight dextran had a higher cardiac output than those receiving high
molecular weight dextran at comparable levels of anemia. These results sug-
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gested that a reduction in outflow impedance in anemic patients is probably
largely determined by changes in whole blood viscosity. The increase of whole
blood viscosity during the correction of chronic anemia [78-79] is in part
responsible for the increase of the peripheral vascular resistance, especially in
the presence of preexistent microvascular abnormalities.
Aim of the study
The aim of the present study was to evaluate the effects of the increased
hematocrit due to ReHuEpo therapy on the circulation of normovolemic chronic
hemodialysed patients.
In chapter I, data are presented of the effects of treatment with ReHuEpo during
the correction phase of hematocrit (± 4 months) on blood volume, plasma
volume, red blood cell volume, macrocirculation (mean arterial pressure, heart
rate, cardiac index, stroke index, systemic vascular resistance), peripheral
oxygenation and skin microcirculatory flow (by transcutaneous oxymetry) in
chronically hemodialysed and normovolemic renal failure patients.
In chapter II, the effects of treatment with ReHuEpo at long term (± 14 months),
after reaching and maintaining the target hematocrit, are presented concerning
fluid status, macrocirculation, cardiac functional and structural parameters.
Moreover, data are given on the long term morphological adaptations of the
pathological capillary loops in the distal row of the finger nailfolds. The func-
tional and structural aspects and their possible (patho-)physiological signific-
ance are subsequently discussed.
In chapter III, the data are given on the study to the effects of the increased
hematocrit during treatment with ReHuEpo on dialysis fluid handling and
plasma volume preservation in chronic renal failure patients maintained on
hemodialysis under standardized conditions. The results are presented on dia-
lytic changes in plasma oncotic pressure, osmolality and hematocrit, but also on
the changes in hemodynamic and cardial function (mean arterial pressure,
cardiac output, stroke volume, left ventricular end diastolic and end systolic
diameters, fractional fiber shortening) and humoral substances known to be
involved in dialytic hemodynamic regulation and stability (plasma adrenaline
and noradrenaline, atrial natriuretic factor).
In chapter IV the data of direct and indirect dialysis fistula function analysis (by
Duplex doppler ultrasonar scanning and spectral analysis) are given before and
after treatment with ReHuEpo. Moreover, the effects on venous pressure in the
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extracorporeal dialysis circuit and the heparin need during dialysis, macrocircu-
latory indices, rheological parameters and indices of primary hemostasis are
studied.
Multiregression analysis is subsequently used to interrelate potential risk
factors for shunt thrombosis as independent variables with the fistula flow
parameters as dependent factors.
In chapter V the results are presented of the measurements of the effects of
treatment with ReHuEpo on indices of primary hemostasis (platelet count,
bleeding time, spontaneous and ADP induced platelet aggregation) but also on
other hemostatic (antithrombin III, protein-C antigen and activity, total and free
protein-S antigens) and fibrinolytic parameters (tissue plasminogen activator
antigen, plasminogen activity, plasminogen activator inhibitor activity).
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Abstract
In 9 chronic hemodialysis patients, treated with recombinant human erythro-
poietin (ReHuEpo), longitudinal studies were performed to investigate possible
changes in macro- and microcirculatory parameters during normovolemia, as
assessed echographically by determining the inferior vena cava diameter and
adjusting dialysis dry weight. Hematocrit increased from 19 ± 4 to 33 ± 5%
(p<0.001). Systemic vascular resistance increased from 1020 ± 259 to 1283 ±
245 dyne/s/cm' (p<0.02), while mean arterial pressure remained unchanged.
Cardiac index decreased (4.9 ± 1.4 to 3.8 ± 0.9 liters/min/m^; p<0.02), caused
by a decrease in heart rate (87 ± 21 to 75 ± 16 beats/min p<0.02) and stroke index
(59.9 ± 15.2 to 51.0 ± 10.7 ml/min*; p<0.02). Red blood cell volume increased
(468 ± 105 to 858 ± 203 ml/nW, p<0.001) and plasma volume decreased
inversely (['*'l] - albumin; 2008 ± 338 to 1664 ± 225 ml/min^; p<0.001),
whereas total blood volume remained unaltered (2476 ± 397 to 2518 ± 352
m l W ; n.s.). Total body weight increased (57.8 ± 12 to 62.1 ± 12 kg; p<0.02),
indicative of an anabolic effect of ReHuEpo therapy. Skin capillary circulation
as measured by transcutaneous oxymetry at 37°C skin temperature impaired,
reflected by the increase of the time to peak after arterial occlusion (82 ± 21 to
121 ± 25 s; p<0.02). The reactive hyperemic response following the release of
occlusion showed a significant increase at high hematocrit (10.7 + 4.2 to 16.6 ±
5.3 mmHg; p<0.02), whereas resting transcutaneous P02 values showed a slight
but not significant increase (2.3 ± 1.3 to 4.7 ± 3.3 mmHg; n.s.). The high number
of pathological capillaries in hemodialyzed patients might be an additional
factor for the increase in systemic vascular resistance.
Introduction
Recombinant human erythropoietin (ReHuEpo) has been found to be a success-
ful treatment of anemia in chronic renal failure [1-6]. The degree and rate of the
increase in hematocrit (Hct) are dose dependent and compromised by the
presence of inadequate iron stores, alluminum intoxication and chronic infec-
tious diseases. The subjective and objective quality of life of chronic renal
failure patients is improving during ReHuEpo therapy [7-10]. However, side
effects have been reported, of which hypertension is the most frequent one
[11-13]. The available data from multicenter trials showed a 20-45% incidence
of development or aggravation of hypertension during the correction of renal
anemia by ReHuEpo [14-16]. Predisposing circumstances are preexistent hyper-
tension, a steep increase in Hct and the absolute Hct level achieved [11, 17]. As
a possible explanation for the increase in blood pressure, several authors re-
ported an increase in systemic vascular resistance (SVR), generally explained
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by a reduction of the anoxic vasodilation related to chronic anemia and by an
increase in whole blood viscosity. The increased blood viscosity should be
related to the reported qualitative and quantitative structural pathological capil-
laries in chronic renal failure and dialyzed patients [18-19], which could lead to
microcirculatory flow disturbances. In this regard, and especially in the presence
of pathological capillaries the actual fluid state also seems to be a crucial factor
in macro- and microcirculatory dynamics [20].
The estimation of dialysis dry weight, based on clinical parameters, is
unreliable [21]. During ReHuEpo treatment, the determination of dialysis dry
weight is even more difficult, due to the increased Hct and the reported weight
gain due to anaboiism. As previously shown, serial echographic determination
of the inferior vena cava provides accurate information about the actual fluid
state and allows the adjustment of the optimal dialysis dry weight to the data
obtained [22-23]. In this way, normovolemia can be reached and maintained
throughout the period of ReHuEpo treatment.
The aim of this study was to investigate the effects of ReHuEpo treatment on
macro- and microcirculatory parameters in chronic hemodialysis patients, vigor-
ously maintaining the normovolemic state.
Patients and methods
Nine chronic hemodialysis patients (6 females, 3 males) with anemia were
selected for macro- and microcirculatory evaluations during an 18-week period
of ReHuEpo therapy. The mean age of the group was 42.1 years (28-70 years)
and the mean duration of dialysis 6.6 years (1-14 years). Patients with severe
hyperparathyroidism, signs of aluminium intoxication, diabetes mellitus or a
history of clinically obvious cardiovascular disease were excluded.
All patients were normotensive at entrance of the study with or without
antihypertensive medication, 6 of them using beta-blocking agents and 4 of the
patients in combination with vasodilating drugs. Twenty-four hours before the
investigations, all vasoactive medication were temporarily stopped. The studies
were performed 20-24 hours after dialysis, the moment of optimal plasma
volume preservation [24], at regular intervals during the treatment period of 18
weeks. Thus, patients were studied longitudinally and served as their own
controls (group A).
To obtain information about the number of pathological capillaries in hemo-
dialyzed patients, the morphology of the nail fold capillaries was studied in 20
chronic hemodialysis patients (group B). The mean age of these patients was
52.1 ± 20.2 years and they were on dialysis treatment for 3.3 ± 2.6 years. The
results were compared with capillary morphology in 20 age and sex matched
normal controls. ;
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Furthermore, 14 sex and age matched normal controls were studied to
compare the outcomes of functional microcirculatory evaluations in this group
(group C) with the results in group A at high Hct levels after 18 weeks of
therapy.
ReHuEpo (Eprex, Cilag, Belgium) was administered intravenously 3 times a
week after dialysis in group A, according to the so-called 'low and slow' dose
schedule, starting at an initial dose of 50 U/kg. Adjustments of the dose were
done monthly, according to the response, defined as an increase or decrease of
5% or more as compared to the preceding Hct value. The target hemoglobin
value was 6.2-7.5 mmol/1. Oral iron suppletion up to 600 mg a day was given in
all but 2 patients, who obviously had adequate iron stores.
Hematological parameters were determined weekly, using routine laboratory
methods. Iron parameters (serum ferritin, transferrin, total iron binding capacity)
were investigated at monthly intervals.
The actual fluid state was determined and maintained by the serial assessment
of the inferior vena cava diameter and the collapsibility index by means of
echography. The measurements were performed with the patient in the suppine
position after 10 minutes of rest. The transducer was placed in the subxiphoidal
region, and long and short axis views of the inferior vena cava were recorded,
just below the diaphragm in the hepatic segment. Simultaneously, a conven-
tional electrocardiogram (ECG) was recorded. To avoid interference with A and
V waves, respectively, measurements of the diameter were done just before the
P wave on the ECG. The optimal collapsibility was registrated just at the
beginning of deep inspiration to avoid valsalva-like manoeuvers [22]. To correct
for interindividual differences in constitution, the data were corrected for body
surface area in square meters. Then, the patients' dry weight could be adjusted
to the normal range. The inter- and intra-observer variability of this method have
been reported to be 5 and 2.5% for the diameter and <10 and 2.5% for the
collapsibility index, respectively [21-22].
Mean arterial pressure (MAP; mmHg) and heart rate (beats/min) were re-
corded during a 1-hour period of rest with the patient in the sitting position, by
means of the Penaz method (Finapress BP monitor, Ohmeda 2300). The maxi-
mal difference between the MAP measured by this method and the pressure
measured intra-arterially is less than 8 mmHg [25].
Stroke volume was calculated from the cross-sectional area of the aortic valve
and the maximal integral flow velocity in the ascending aorta, both assessed in
early systole with the use of a Hewlett-Packard (770 20A) 3.5-MHz Duplex
scanner. From these variables, cardiac output was calculated [26-28]. The inter-
and intra-observer variability of this method have been reported to be less than
10% [29]. SVR was calculated using the conventional formula. Right atrial
pressure could be delineated from the curvilinear relationship with the inferior
vena cava diameter [21].
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Plasma volume was determined using the '^I-albumin method [30]. Red
blood cell (RBC) volume was calculated according to the serial Hct method [31].
Morphological studies of the capillary circulation were done with the use of
intravital videomicroscopy of the fingernail fold capillaries (Philips Video 40
camera, Leitz Wetzlar microscope, Sony videorecorder). The morphology of the
capillaries was determined in the distal row (videoscreen 1800 fim, magnifica-
tion xl60), with special attention to the configuration of the capillaries.
In groups A and C, transcutaneous oxymetry was performed at 37°C skin
temperature on the dorsum of the hand on the side without dialysis fistula with
the arm at heart level. Transcutaneous P02 (TcPo2) levels at rest, the peak value
and the time to peak during the reactive hyperemia response after 3 minutes of
arterial occlusion were determined [32-35]. The reproducibility of this method,
expressed as percentage of variation from the means for each individual in serial
determinations in several weeks, is about 10% [36]. TcPo2 recordings were
made with a Radiometer TCM2TC oxygen monitor (Copenhagen, Denmark).
For statistics the paired Student t test was used for integral analysis. The
nonpaired t test for the difference in means was used to compare patient groups
with controls. A p value of <0.05 was considered to be significant.
Results
Throughout the study Hct increased in the ReHuEpo treated patients from 19 ±
4 to 33 ± 5% (p<0.001), while normovolemia was maintained as indicated by
the diameter and collapsibility index of the inferior vena cava. Total blood
volume indeed remained un-
changed, whereas RBC volume in-
creased significantly in accordance
with the rise in Hct, and plasma vol-
ume decreased inversely (figure 1).
Body weight increased significantly
from 57.8 ± 12 to 62.1 ± 12 kg
(p<0.02) during the treatment
period, indicative for an anabolic ef-
fect of ReHuEpo therapy. The mac-
rocirculatory results are presented in
figure 2. MAP did not change signi-
ficantly. SVR increased signifi-
cantly from values in the normal
range to values above the upper nor-
mal limit of 1200 dyne/s/cm"*. Car-
diac index decreased significantly,
Figure 1: Effects of ReHuEpo treatment on
RBC volume (•), plasma volume (D) and blood
volume (plasma volume + RBC volume).
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Figure 2: Effects of ReHuEpo on Het (a; %), MAP (b; mmHg), SVR (c; dyne/s/cm'), cardiac
index (d; 1/min/m )^, heart rate (e; beats/min) and stroke index (f; ml/m*). *p<0.05; **p<0.02;
***p<0.001: compared to values before (0 weeks) ReHuEpo treatment.
due to a decrease in heart rate and stroke index.
In the 20 chronic hemodialysis patients (group B), the number of pathological
capillary loops in the distal row of the fingernail fold has increased compared to
normal subjects (48.7 ± 18.1 and 9.8 ± 6.7%, respectively; p<0.001), with
tortuosity in the arterial limb of the vessel, generally associated with a pro-
nounced venodilation (figure 3).
The results of TcPo2 measurements in groups A and C are presented in table
1. The resting TcPo2 values showed a small insignificant increase during
Figure 3: Pathological capillary loop with arterial tortuosity (arrow), generally accompanied
by venous vasodilation.
Table 1: TcPo2 before (0 weeks) and during (6, 12 and 18 weeks) ReHuEpo treatment in
dialyzed patients (group A) compared to normal controls (group C) at optimal Hct
Parameter Patients (group A; n=9)
0 weeks 6 weeks 12 weeks 18 weeks
Controls
(group C;
n=14)
Rest TcPo2, mmHg 2.3 ±1.3 3.4 ±1.5 2.7 ±1.1 4.7 ± 3.3» 3.2 ±1.5
PeakTcPo2,mmHg 10.7 ±4.2 16.0 ±4.3 15.8 ±3.4 16.6 ±5.3"-" 14.9 ±6.2
TTP, s 82 ±21 95 ±11 105 ± 17= 121 ± 2 5 ^ 81 ± 16
Hct, % 33 ± 5 40.2 ± 4
*p=n-s. and *>p<0.001 versus controls; <=p<0.05 and <"p<002 versus values before ReHuEpo
therapy. TTP = time to peak after arterial occlusion.
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ReHuEpo treatment with an improvement in 6 out of 9 patients. A similar but
significant effect was noted in peak TcPo2 levels during reactive hyperemia after
3 minutes of arterial occlusion. The time necessary to reach the maximal peak
value after occlusion increased significantly at 18 weeks of ReHuEpo therapy
(Hct 33 ± 5%) compared to the initial value and to the values in the sex and age
matched controls at an Hct of 40.2% (121 ± 25 and 81 ± 16 s, respectively;
p<0.001).
Discussion
The development of ReHuEpo was expected to have an enormous impact on the
quality of life of dialyzed patients. However, the increased morbidity, i.e. a
higher incidence of dialysis fistula clotting, a decrease in dialysis efficacy and
the occurrence of cerebral convulsions and hypertension [37], still raises the
question as to whether there is an optimal Hct, because of the obvious relation
between these complications and the rate of increase in Hct and the absolute Hct
value achieved [17]. Hypertension, the incidence of which is estimated to be on
the average of 30% and especially occurring in the preexistent hypertensive
individual and during a steep increase in Hct, is generally related to an increase
in S VR. The incorrect estimation of dialysis dry weight, often done on the basis
of clinical parameters, may also play a crucial role in the incidence and patho-
physiology of ReHuEpo related hypertension [17, 38].
Since the fluid status has an important, but to our opinion still underestimated,
impact on micro- and macrocirculatory parameters in dialyzed patients, we
performed our studies of the hemodynamic effects of ReHuEpo therapy in the
normovolemic state. The actual volume state was determined by serial echo-
graphic assessment of the inferior vena cava diameter and collapsibility para-
meters, known to be in good correlation with blood volume, mean arterial
pressure and plasma a-human atrial natriuretic peptide levels [21]. As a result,
total blood volume did not change throughout the study. The increase in RBC
volume was accompanied by a decrease in plasma volume. Total body weight,
however, increased, probably due to anabolism during ReHuEpo therapy [39-
41].
While maintaining the normovolemic state, MAP did not increase in our
patients during ReHuEpo therapy, although there was a significant increase in
SVR. Cardiac index decreased significantly, due to a decrease in heart rate and
stroke volume.
Except for the findings of Verbeelen et al [42], other authors also reported a
decrease in cardiac output, stroke volume and heart rate, and an increase in SVR
during ReHuEpo therapy [34, 43-45]. In most of these studies, MAP increased
significantly; however, the overall incidence of hypertension during ReHuEpo
therapy reported in the literature is only about 30% with a range of 20-45%.
Similar findings were reported by Neff et al [46], who increased the Hct of
anemic diaiyzed patients by serial blood transfusion to at least 40% within 6-12
weeks, and saw an increase in the peripheral vascular resistance and a decrease
in cardiac index, while MAP increased. Williams et al [47], increasing the Hct
with an average value of 8% in a large and varied dialysis population, did not
find an increase in predialysis blood pressures within 1 week after the blood
transfusion. More detailed hemodynamic investigations unfortunately were not
performed in this study [47].
Obviously, not ail ReHuEpo treated patients develop hypertension, despite
an increase in SVR, and it has been reported that individuals prone to hyperten-
sion had relatively high pre- and posttreatment cardiac output levels as com-
pared to other patients treated with ReHuEpo, but remaining normotensive [45,
48]. In general, cardiac index and stroke volume decrease during the correction
of anemia by ReHuEpo therapy, whereas SVR increases. Whether the MAP will
rise, depends on the rate of increment in Hct, the ultimate Hct level achieved,
the preexistence of hypertension and last but not least on the actual fluid status.
It is tempting to speculate on the pathogenesis of the decrease in stroke
volume and the increase in SVR during ReHuEpo treatment. Since Löw et al
[49] found an improvement of myocardial function, as indicated by an increased
ejection fraction, an increased circumferential fiber shortening velocity and a
slight decrease in stroke volume, it could quite well be that the decrease in
cardiac pump function results from a diminished venous return and hence
cardiac filling. The decrease in venous return could result from the increase in
blood viscosity and SVR, accompanying the increase in Hct during ReHuEpo
therapy. The improvement of peripheral oxygenation, by the increase in RBC
mass and the persisting low hemoglobin oxygen affinity [50], reduces the
necessity of compensatory mechanisms like sympathetic overactivity. Unfortu-
nately, we did not determine the serum catecholamine levels in our study.
Hauser et al [51] determined plasma catecholamine levels in hemodialyzed
patients, treated with ReHuEpo but these investigations did not reveal a statisti-
cally significant difference in predialysis as well as postdialysis levels between
the ReHuEpo treated diaiyzed patients and control diaiyzed patients [51].
The increase in SVR during ReHuEpo therapy could be explained by the
improvement of peripheral oxygenation, which will reduce anoxic vasodilation.
Unexplained, however, is the finding that SVR increases to levels above normal.
It is unlikely that high levels of catecholamines are responsible for these
relatively high SVR levels, since the plasma catecholamines do not seem to be
increased under these circumstances [51]. ReHuEpo itself seems to have no
direct vasopressor effect, but the possibility that it interferes in the vasoconstric-
tion induced by hormones such as noradrenaline and angiotensin II cannot be
29
excluded [52]. The increase in SVR is obviously also dependent on structural
and functional changes in microcirculatory vessels [14].
The observed histological cutaneous microangiopathy in chronic hemo-
dialysis patients [18-19] and the increased percentage of pathological tortuous
capillaries in the nail fold as found in the present study, might contribute to the
increase in SVR when viscosity is increased during ReHuEpo treatment. The
functional alterations in the microcirculation, as reported in this study, are
supporting this hypothesis. Rest values of TcPo2 and peak values during reactive
hyperemia at 37°C skin temperature both showed an increase at higher Hct
levels, suggesting an improvement of peripheral oxygenation. However, except
for the postocclusive peak TcPo2 values, these changes did not reach the level
of significance. Time to peak value, after arterial occlusion, inducing arterial
vasodilation, increased significantly at higher Hct levels. After 18 weeks of
ReHuEpo treatment (Hct 33 ± 5%), time to peak was significantly longer in the
patient group than in normal controls with an average Hct of 40.2%. No
differences existed in the time to peak values of the patient group at low Hct
level (19 ± 4%) compared to the control group at high Hct level. The latter data
suggest an impairment of capillary flow in hemodialyzed patients during the
correction of anemia by ReHuEpo. This could be the result of the increased
blood viscosity at higher Hct levels in combination with the pathological
microcirculation noted in dialyzed patients.
The increased incidence of cerebral convulsions during ReHuEpo therapy
[37], not consistently related to hypertension, for example might find its patho-
physiologic explanation in the combination of these compromising factors.
Blood cell velocity in the cerebral vessels has been shown to decrease by
single-photon and emission computer tomography with '^Xe [53] and espe-
cially in case of an underestimated dialysis dry weight, the subsequent strong
decline of cardiac filling pressure and exaggerated hemoconcentration during
dialysis might critically compromise cerebral perfusion.
In conclusion, maintaining the normovolemic state, ReHuEpo therapy in
dialyzed patients did not lead to a rise in MAP despite the rise in SVR. The
combination of pathological microcirculatory vessels and changes in rheology
might in part explain the increased SVR, in consequence leading to disturbances
in microcirculatory flow.
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Abstract
Erythropoietin therapy (ReHuEpo) at short-term leads to an increase in systemic
vascular resistance, a decrease in cardiac index and skin microcirculatory flow.
Long-term adaptive changes might occur. We studied the effects of ReHuEpo
therapy on macrocirculation and skin microcirculation in 8 normotensive and
normovolemic hemodialysis patients before and after respectively 4 and 14
months of treatment. The reported macrocirculatory changes at short term were
at long term not significantly different as compared to the initial values. Mean
arterial pressure remained unaltered, as might be explained by the slow correc-
tion of the hematocrit and the decrease in cardiac output in all initially longlast-
ing normotensive patients, who were maintained normovolemic. Left
ventricular end diastolic dimensions decreased and also left ventricular muscle
mass decreased depending on the initial left ventricular muscle mass. Skin
oxygenation improved whereas maximal capillary flow decreased both at short-
and long-term ReHuEpo treatment. The number of capillaries in the nailfold
remained unchanged. However, the percentage of tortuosity decreased signifi-
cantly during ReHuEpo therapy.
Introduction
Chronic anemia is associated with functional hemodynamic changes, like in-
creased cardiac output and heart rate, and decreased peripheral vascular resist-
ance [ 1 -2]. Also structural cardiovascular changes are related to chronic anemia,
as there are an increase in left ventricular end diastolic diameter and left
ventricular muscle mass [3-6].
Correction of the anemic state by recombinant human erythropoietin (Re-
HuEpo) therapy in patients with renal anemia induced a decrease of cardiac
output, due to a decrease of heart rate and venous return, and an increase of
systemic vascular resistance [7-9].
The increase of systemic vascular resistance has been attributed to a loss of
hypoxic vasodilation, to changes in humoral effects on resistance and to in-
creased blood viscosity. In normal physiology approximately 50% of the sys-
temic vascular resistance is located at the microcirculatory level (eg. vessels
with an internal diameter of 100 (im or less). The microcirculation of dialysis
patients, as studied by intravital microscopy in the finger nailfold, revealed an
increased incidence of pathological tortuous capillaries, especially in hypertens-
ive but also in normotensive dialysis patients as compared to normal controls
(61%, 35%, 8% respectively) [10]. These microcirculatory changes in combina-
tion with the increased blood viscosity at higher hematocrit levels could in part
be responsible for the increased peripheral vascular resistance during the correc-
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tion of renal anemia with ReHuEpo. The observed morphological changes in the
microcirculation of dialysis patients could be related to uremic toxins, hyperten-
sion, and anemia, and turned out to be reversible after renal transplantation [11].
The effect of ReHuEpo on the microcirculatory morphology, however, is yet
unknown.
Correction of renal anemia by ReHuEpo resulted also in macrocirculatory
structural changes, like a decrease of preexistent left ventricular hypertrophy
[12-18] and left ventricular dimensions [19-22]. The decrease of venous com-
pliance during ReHuEpo therapy [7] is probably not related to structural change-
s, but most likely to an increase in venous tone.
The aim of the current study was to investigate whether the reported early
hemodynamic changes, i.e. increased systemic vascular resistance and de-
creased cardiac output, persisted in the course of longterm treatment with
ReHuEpo. Furthermore, we investigated if longterm treatment with ReHuEpo,
improving peripheral oxygenation, improved the structural abnormalities of the
cardiovascular system of patients with end-stage renal failure, at both the
macrocirculatory and microcirculatory level. Because hypertension also induces
structural vascular changes, we investigated the effect of longterm ReHuEpo
therapy on these parameters only in dialysis patients with longstanding nor-
motension.
Patients and methods
Fifteen normotensive (postdialytic blood pressure < 140/90 mmHg) chronic
hemodialysis patients (group A; 5 females, 10 males) were initially included in
the study. The mean age of the group was 46 ± 17 years (28-80). The patients
were dialysed 3 times a week, using bicarbonate buffer and a biocompatible
membrane (GFS 16, Gambro, Haemophane). The calculated Kt/V was >1 for
each dialysis treatment.
Patients with severe hyperparathyreoidism, signs of aluminium intoxication,
diabetes mellitus or cardiac dysfunction, defined as a left ventricular ejection
fraction <40%, and/or clinically important valvular disease, were excluded. Also
patients with left ventricular asynergy were considered not to be eligible.
All patients were normotensive at entrance of the study (for more than 6
months) with or without antihypertensive medication, 7 patients were using
calcium entry blockers. None of them used other vasodilating agents, beta-
blocking agents or ACE inhibitors. Twentyfour hours before the investigations
all antihypertensive medication was temporarily stopped. The studies were
performed 20-24 hours after dialysis, the moment of optimal plasma volume
preservation [23]. The patients were studied longitudinally over 1 year and
served as their own controls.
Furthermore, 8 sex and age (52.5 ± 13 years) matched normal controls (group
B) were studied to compare the outcome of the functional microcirculatory
evaluations in this group with the results obtained in the patient group. The
hematocrit in group B was 39 ± 3%.
In group A ReHuEpo (Eprex, Cilag, Belgium) was administered intravenously
3 times a week after every dialysis, according to the so called "low and slow"
dose schedule, starting at an initial dose of 50 U/kg. Adjustments of the dose
were carried out monthly according to the response as defined by an increase or
a decrease of 5% or more as compared to the preceding hematocrit value. The
target hemoglobin was set upon 10.5-11.6 g/dl. Oral iron suppletion upto 600
mg/day was given in all patients, and parenteral iron was temporarily used in
only one patient.
Hematological parameters were determined initially at weekly intervals and
two weekly during the maintenance fase after the target hematocrit had been
reached, using routine laboratory methods. Iron parameters (serum ferritine,
transferrin, total iron binding capacity) were checked every month.
The actual fluid state was determined and normovolaemia was maintained,
using the method of serial assessment of the inferior caval vein diameter and the
collapsibility index by means of echography [24] and adjusting the individual
dialysis dry weight to the normal range. The inter- and intra-observer variability
for our cardiovascular research laboratory was for the vena cava diameter less
than 5% and 2,5% respectively, and for the collapsibility index less than 10%
and 2,5% respectively.
The different macro- and microcirculatory parameters were evaluated before
the study, after reaching the target hematocrit and after more than one year of
ReHuEpo therapy.
Afacroc/rcM/ar/on
The functional aspects of the macrocirculation were studied as follows:
Mean arterial pressure (MAP, mmHg) and heart rate (HR, beats/min) were
recorded during a one hour period of rest with the patient in the sitting position,
using the Penaz method (Finapress BP monitor, Ohmeda 2300) [25-26].
Echocardiographic registration was performed, according to the recommen-
dation of the American Society of Echocardiography [27-28]. Stroke volume
(SV, ml/min) was determined from the data of the cross-sectional area of the
aortic valve and the maximal integral flow velocity in the ascending aorta during
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early systole with the use of a Hewlett Packard (7700 20a) 3.5 megaherz Duplex
scanner. Cardiac output (CO, 1/min) was determined from SV and heart rate
[29-31]. The intra- and interobserver variability of this method have been
reported to be less than 10% [30]. Stroke index (SI) and cardiac index (CI) are
SV and CO per square meter body surface area.
Subsequently systemic vascular resistance (SVR, dyne/sec/cm"') was calcu-
lated using the conventional formula (SVR = [MAP-RAP] :CO x80; RAP = right
atrial pressure, which value can be delineated from its curvilinear relationship
with the measured inferior caval vein diameter [24]).
Left ventricular ejection fraction (EF, %) as well as fractional fiber shortening
(FFS) were calculated according to Von Bibra et al [32].
Plasma volume (PV, ml) was determined using the I ^ 'albumin method [33],
whereas red blood cell volume (RBCv, ml) was calculated according to the serial
hematocrit method [34],
The geometric aspects of macrocirculation were studied by means of additional
echocardiographic registrations including: left ventricular end-diastolic
diameter (LVEDD, mm/m^) and volume (LVEDV, ml/m*) as well as end-sys-
tolic diameter (LVESD, rnm/m^) and volume (LVESV, m m / m \ using the
Teichholz formula [35]. Also the posterior wall end-diastolic thickness (PW-
EDWT, mm/m^) and interventricular septal wall thickness (IVS-EDWT,
mm/m^) were measured, as was the left atrial diameter (LAD, mm/m^). For the
determination of total left ventricular volume (LVV, ml/m^) and left ventricular
mass (LVM, gram/m^), the formula of Devereux and Reichek was applied [36].
The correlation of LVM, calculated according to this method, with necropsy
findings has been observed to be high (r=0.92) with only 6% of overestimation
and with a very low intra- and interobserver variability [37].
Functional information about the microcirculation was obtained with transcuta-
neous oxymetry (radiometer TcM2Tc oxygen monitor, Copenhagen, Denmark)
at a skin temperature of 37°C [38-43]. The electrodes were placed on the dorsum
of the hand at the side without dialysis fistula and with the arm at heart level.
Transcutaneous PO2 (TCPO2) levels at rest (mmHg) as well as the peak value
(mmHg) and the time to peak value (TTP, sec) during reactive hyperaemia
following the release of a 3 minutes arterial occlusion, were determined. The
patient group as well as the control group were evaluated by this method, the
reproducability of which, expressed as the percentage of variation from the
means for each individual in serial determination, has been reported to be ± 10%
[42].
Anatomical evaluations of the capillary circulation were done with the use of
intravital videomicroscopy of the finger nailfold capillaries (Philips video 40
camera, Letz Wetzlar microscope, Sony videorecorder). The capillaries were
studied in the distal row (videoscreen 1800 Jim, magnification xl60) paying
attention not only to the number of capillaries, but also to their morphology i.e.
tortuosity. Tortuosity was defined as one or more loops in the arterial limb of
capillaries in the distal row. Tortuosity was scored as a percentage of the total
number of capillaries in the distal row. The capillaries were studied in 3
microscopic fields in the nailfold. The skin temperature of the examined finger
during the investigation was 30 ± 1.6°C.
Statistical analyses were done with the Wilcoxon Rank-sumtest for intra-group
results. The Mann-Whitney signed rank test was used to compare patients with
controls. The data were expressed as means ± S.D. Correlation coefficients were
determined by the Pearson Rank test. In all tests a p-value of <0.05 was
considered to be significant.
Results
Of the 15 patients initially included in the study only 8 of them could be
evaluated at long term. Of the 7 patients not available for follow-up 3 were
transplanted with a postmortal donor kidney, 1 patient changed to CAPD, 1 died
at home by an unknown cause and 2 patients refused to participate in further
evaluations.
The mean age of the evaluable group of 8 patients was 50.6 ±15.6 years
(31-80) with a mean duration of dialysis before the start of the study of 26
months (5-84).
During the correction phase of treatment with ReHuEpo, hematocrit (Ht, %)
increased from 21 ± 2 to 36 ± 4% (p<0.001). During the maintenance phase, after
the target Ht had been reached at 4 ± 1 months (period I) and upto 14 ± 2 months
(period II) of follow-up, Ht remained unaltered.
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Table 1: Hematocnt, hcmodynamic results and body weight before and during ± 14 months
of ReHuEpo therapy in 8 normotensive dialysis patients
Ht(%)
MAP (m/n//g)
SI (m//fc/m^
Cl f//«Jj«ym^j
SVR (dynWrcc/
FFSf%)
BW to)
Pre
21 ±2
95 ±9
52 ±8
4.0 ±0.7
cm"*) 1038 ± 164
57 ±7
36 ±3
66.7 ±8
*
• • •
• •
• •
• *
I
36 ±3
101 ±11
47 ±7
3.4 ± 0.6
1320 ±221
54±9
34±3
70.3 ± 8
II
36 ±3°
99 ±12
52 ±12
3.7 ±1.0
1235 ±368
57 ±7
34±3
71.7 ±9"
Significant differences are indicated by: *p<0.001; **p<0.02; •••p<0.05; °p<0.001; The
astenxes represent significant differences between short-term results and the initial values.
The open circles represent significant differences between the long-term results and the initial
values; Pre : before ReHuEpo treatment; I: period I correction phase to reach target hcmuto-
crit level; II: period II maintenance phase at target hematocnt level.
A/acrorircM/ar/on
A) Functional aspects (table I):
MAP did not change significantly. HR (-14.2%) as well as stroke index (SI)
(-9.6%) and cardiac index (CI) (-15.2%) decreased significantly at short term.
However, at longterm the differences as compared with the initial values were
not significant. SVR increased significantly during the correction phase with
+29.2% and again the difference at long term was not significant as compared
to the initial value. EF and FFS did not change during the whole period of
investigation. The data of BV and derived voluminae are depicted in figure I.
PV decreased inversely with RBCv to remain unchanged at long term, whereas
BV remained unaltered. Body weight (BW; kg) increased significantly at short
term but remained unaltered at long term treatment.
B) Geometrical aspects (table II):
The indexed LVEDV (-10.8%) and LVEDD (-8%) decreased significantly
during the correction phase and remained unaltered in the maintenance phase of
Ht, whereas the indexed values of LVESV and LVESD did not change at all.
The PW-EDWT decreased, whereas the IVS-EDWT did not change. Also LAD
remained unchanged. The indexed LVV as well as the LVM did not change
significantly. However, in 6 out of 8 patients, LVM decreased with -20%. In the
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Figure I: Blood volume (BV),
plasma volume (PV) and red
blood cell volume (RBCV) dur-
ing treatment with ReHuEpo.
Significant differences as com-
pared with the initial values are
indicated:
•*p<0.01 (pre vs. -I) ;
***p<0.001 (pre vs.-I); Pre: be-
fore ReHuEpo treatment; I:
period I correction phase to
reach target hematocrit level; II:
period II: maintenance phase at
target hematocrit level.
Time
Table 2: Echocardiographic results of 8 normotensive dialysis patients before and during
long-term ReHuEpo therapy
LVEDV/m* Cm/;
LVEDD/m* fmm)
LVESV/m^ (m/;
LVESD/m* COT/M)
PWEDWT/m* (mm;
ivsEDWT/m^ fmmj
LAD/m2 (mm;
LVV/m2 (m/;
LVM/m* («r;
Pre
71 ±18
29 ± 3
25 ± 9 • "
18 ±2
6.0 ±0.8
6.2 ±1.3
26 ±3
275 ± 99
90.6 ± 29.6
• •
• •
I
62 ±13
27 ±3
24 ±8
18 ±3 ' '
5.8 ± 1.1
5.8 ±0.9
25 ± 3
260 ±76
84.6 ±26.7
n
56 ±13°
26 ± 3
21 ±7
17 ± 3
5.5 ±0.7
5.8 ±1.0
24 ± 3
236 ±32
76.0 ±12.0
Significant differences are indicated by: **p<0.02; °p<0.001; The asterixes represent signi-
ficant differences between short-term results and the initial values. The open circle represents
a significant difference between the longterm result and the initial value; Pre: before Re-
HuEpo therapy; I: period I correction phase to reach target hematocrit level; II: period II
maintenance phase at target hematocrit level. • . - ,j ' > . . ! ; "
150-1
120-
9 0 -
60
Figure 2: Individual values of left ventri-
cular mass (LVM) during treatment with Re-
HuEpo.
Pre : before ReHuEpo treatment; I: period I
correction phase to reach target hematocrit
level; II: period II maintenance phase at tar-
get hematocrit level.
Pre
Tknt
remaining 2 patients with a normal LVM, a small increase of LVM was
observed with 44.5%, all of them however still remaining within the normal
range (figure II).
A strong inverse relation was found between the initial LVM(i) and the
decrease of the left ventricular muscle mass after long term treatment with
ReHuEpo (r=0.92, p=0.001).
A) Functional aspects: '
The results of the TcpCte measurements at 37°C subelectrode skin heating are
depicted in figure 3 and compared to the data of the control group.
After reaching target Ht-level at 37°C, a significant increase in TcpCh resting
values and peak TcPO2 values following the release of an arterial occlusion was
observed, suggesting an improvement of peripheral oxygenation. However, the
TTP also increased significantly, suggesting an impairment in capillary flow. At
long term treatment the same data were found (figure 3).
B) Anatomical aspects:
The data of intravital microscopy of the nailfold capillaries regarding the
number of capillaries and the percentage of tortuosity, as studied in the distal
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Figure 3: TcPO2 rest and peak values (mmHg), time to peak (TTP)
and hematocrit in the patient group A during treatment with Re-
HuEpo and in control subjects B. Significant differences are indi-
cated between the two examinations and the initial values, and in
addition in the TTP graph between the two examinations and the
control group: *p<0.05; **p<0.01; ***p<0.001; Pre : before Re-
HuEpo treatment; I: period I correction phase to reach target hema-
tocrit level; II: period II maintenance phase at target hematocrit level.
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Table 3: Microvascular structural data on 8 normotensivc dialysis patients before and during
long-term ReHuEpo therapy
Number of
capillaries
Tortuosity
Pre
9.7 12.3
(5.7-13)
34.7123.1
ns
<0.05
I
11.412.6
(7.8-15)
10.217.2
ns
ns
II
11.412.5
(7.6-14)
7.115.6°
°p<0.05; The open circle represents a significant difference in percentage tortuosity between
the longterm result and the initial values; Pre: before ReHuEpo therapy; I: period I correction
phase to reach target hematocrit level; II: period II maintenance phase at target hematocrit
level.
row, are given in table III. The total number of capillaries/ videoscreen did not
change during ReHuEpo therapy. However, there was a significant decrease in
the percentage of tortuous capillaries in the distal nailfold during ReHuEpo
therapy.
Discussion
Correction of chronic renal anemia by ReHuEpo therapy, with in consequence
an improvement of tissue oxygenation, revealed a decrease of cardiac output and
an increase of systemic vascular resistance, leading to a significant increase of
blood pressure in about 30% of the treated hemodialysis patients. Especially the
patients with pre-existent hypertension were prone to develop a more severe
hypertension [44].
The improved peripheral oxygenation with subsequent loss of autoregulatory
hypoxic vasodilation [45-46], recovery of the lost responsivity of peripheral
vascular smooth muscle cells for certain vasoconstrictor stimuli [47] and the
direct influence of vasoactive humoral substances [48], have been suggested to
be responsible for the increased systemic vascular resistance during treatment
with ReHuEpo. To what extent direct effects of RehuEpo on the resistance
vessels are involved, is still matter of debate [49-51].
Also increased blood viscosity in combination with the observed pre-existent
structural vascular changes in hemodialysis patients could result in an increased
vascular resistance. This hypothesis is supported by the fact that a direct and
non-linear relation has been found between hematocrit and blood pressure [45]
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and that patients with pre-existent hypertension, knowing to have the most
pronounced structural vascular changes, showed a significant rise in blood
pressure [44]. So, functional changes due to ReHuEpo therapy combined with
structural vascular changes could play a role in the increase of the systemic
vascular resistance and blood pressure in ReHuEpo treated hemodialysis pa-
tients. The question is whether on long term ReHuEpo therapy functional and/or
structural adaptations will lead to a normalisation of the hemodynamic state.
In this study cardiac index and stroke index decreased and systemic vascular
resistance increased during short term treatment with ReHuEpo as was also
observed by others [7-9]. Blood pressure did not change significantly while
normovoiaemia was maintained throughout the whole study period as indicated
by the vena cava parameters and the constant total blood volume. Also, the
preexistent normotensive state of all our patients and the decrease in cardiac
output together with the gradual correction of hematocrit during treatment with
ReHuEpo are expected to contribute to the avoidance of hypertension. As
cardiac output is determined by blood volume, heart rate, cardiac contractility
and venous return, the decrease in stroke volume might be secondary to a
decrease in venous return since blood volume, left ventricular ejection fraction
and fractional fiber shortening did not change, which is in agreement with
previous observations [7, 15]. London et al observed a decrease of venous
compliance and a non-catecholamine related increase in venoconstriction in the
extremities as compensation for the decreased venous return and hence cardiac
filling [7].
After long term treatment cardiac index, stroke index, systemic vascular
resistance and blood pressure were not different from values determined after
the target hematocrit had been reached and no significant differences with the
initial values before treatment could be detected anymore.
During treatment with ReHuEpo end-diastolic left ventricular dimension de-
clined, whereas end systolic diameter and volume did not change. The decrease
of left ventricular end diastolic diameter and volume can probably be explained
by a decrease in venous return.
The PW-EDWT decreased, whereas the IVS-EDWT did not change. In our
study the indexed left ventricular mass decreased during ReHuEpo treatment
although not significantly for the whole group. The patients with the highest
initial left ventricular mass showed the most pronounced decrease of left ventri-
cular muscle mass during ReHuEpo therapy, whereas patients with a normal
initial left ventricular muscle mass showed no change. The initial left ventricular
muscle mass was found to correlate with the decrease of left ventricular muscle
mass during ReHuEpo therapy. Blood pressure did not change in any patient and
was in the normotensive range. A progressive decline and even normalisation of
left ventricular mass has also been reported by MacDougall et al [13]. Low et al
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did not find decreases in cardiac wall thicknesses but yet a decrease in left
ventricular mass after 3 and 12 months of treatment with RehuEpo [ 14]. Satoh
et al even observed increases of interventricular wall and posterior wall thick-
nesses together with a significant decrease in heart size in a selected group of
patients with normal cardial function [15]. Canella et al [12] observed a signifi-
cant reduction in left ventricular mass after 3 months of treatment with ReHuEpo
when the target Ht had been reached and a further improvement after 6 months
of treatment, whereas, the initial normal blood pressure remained unaltered as
in our study. This suggests that the left ventricular hypertrophy of uremic anemia
is partly determined by too low a hemoglobin concentration. Because blood
volume also remained unchanged in our study, a decrease in AV fistula load, a
reduction in neurosympathetic tone due to a decrease in plasma catecholamine
levels [12], and/or inactivation of a not yet defined positive inotropic factor in
anemic serum [52], have to be considered as a cause for the reported reversal of
the increased left ventricular mass during treatment with ReHuEpo.
Regarding the functional microcirculatory investigations, a significant short
term improvement in peripheral oxygenation was observed, as was also reported
by Nonnast Daniels [46] and Kreutzig et al [43]. Also at long term we found rest
tissue-PO2 to be higher, although not significant as compared to the pre-treat-
ment value. The observation in the present study that the time to peak tissue PO2
following the release of an arterial occlusion, was increased during short term
treatment, indicates hampering of microvascular flow at high flow rates. At long
term we found still an increased time to peak tissue PO2, although not significant
as compared to the pre-treatment values, but still significant different as com-
pared to the control group with even a higher hematocrit level.
Whereas no change in the number of capillaries in the distal row of the finger
nailfold could be found, videomicroscopy revealed a significant decrease in
tortuosity of the capillaries during short term treatment, an effect that was
maintained after long term treatment with ReHuEpo. This suggests that the
improved skin oxygenation during treatment with ReHuEpo or ReHuEpo itself
has an ameliorating effect on the configuration of the distal skin capillaries
because dialysis treatment and efficacy was not changed during ReHuEpo
therapy. This rapid normalisation of the structure of the capillaries in dialysis
patients has also been reported after succesful renal transplantation [11].
Although there was an improvement of the configuration of distal nailfold
capillaries, this did not result in an improved microvascular circulation at
maximal vasodilation induced by ischemia. This might suggest that there are
still structural abnormalities at the level of the arterioles.
In summary, during long term treatment with ReHuEpo blood pressure re-
mained unchanged. Although there was a significant difference at 4 months in
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cardiac index, stroke index and systemic vascular resistance compared to the
initial values, these differences were not significant anymore at 14 months. The
cardiac function as indicated by the left ventricular ejection fraction and frac-
tional fiber shortening, remained unchanged throughout the whole follow-up
period.
The end-diastolic left ventricular dimensions decreased, for which a de-
creased venous return might be responsible. The left ventricular mass declined,
especially in patients with the highest initial mass.
At short term, skin oxygenation improved whereas maximal capillary flow
decreased during treatment with ReHuEpo and both remained unchanged at long
term. Whereas the number of countable capillaries in the finger nailfold re-
mained unchanged, the percentage of tortuous capillaries decreased signifi-
cantly.
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Abstract
At higher hematocrit levels during recombinant human erythropoietin (Re-
HuEpo) therapy, plasma volume is decreased, while total blood volume is
constant. This could influence osmolality and oncotic pressure changes during
hemodialysis and in consequence plasma volume preservation. Furthermore,
hemoconcentration after hemodialysis will influence blood viscosity and in
consequence venous return and hemodynamic stability.
Nineteen chronic hemodialysis patients were studied during dialysis and
ultrafiltration at low and high hematocrit levels. Plasma volume changes, osmo-
lality and oncotic pressure were studied, as were left ventricular end diastolic
diameter, stroke index and mean arterial pressure. Although compared to low
hematocrit, oncotic pressure increase at high hematocrit was significantly
higher, plasma osmolality at high hematocrit tended to be lower, resulting in a
comparable plasma volume preservation at low and high hematocrit.
There was a significant decrease of stroke index at high hematocrit, which
was related to the decrease of left ventricular end diastolic diameter, a preload
parameter. However, blood volume changes were comparable, indicating a
decreased venous return related to an increased blood viscosity as a possible
cause.
In conclusion, plasma volume preservation is equal at low and high hematocrit
on basis of a counteractive effect of an increase of oncotic pressure and a
decrease of osmolality at high hematocrit. The significant stroke index decrease
at high hematocrit was influenced by the preload change (left ventricular end
diastolic diameter) during hemodialysis at a comparable blood volume change,
indicating changes in venous return which could be related to increased blood
viscosity.
Introduction
Plasma volume preservation plays a pivotal role in dialysis induced hemo-
dynamic instability. The main factors determining plasma volume preservation
are the fluid status [1-3], the used buffer substrate [4-5], the venous compliance
[6-9], the oncotic pressure [10-11] and osmolality changes [12-18].
Erythropoietine (ReHuEpo) therapy of dialysis patients reveals an increase in
red blood cell volume (RBCV) and a decrease of plasma volume, while total
blood volume does not change [19]. Because of the decreased plasma flow
through the artificial kidney at higher hematocrit levels, combined ultrafiltration
/dialysis could have different effects on osmolality and oncotic pressure change-
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s as compared to uitrafiitration / dialysis at lower hematocrit levels. In conse-
quence, this could influence plasma volume preservation.
Whether the decrease of plasma volume induces hemodynamic instability,
will depend on the efficacy of the cardiovascular regulatory mechanisms [2].
Venous return can be maintained by venous constriction, inducing centralization
of blood volume [7, 20-21]. Another important factor for venous return is the
total blood viscosity, which among others depends on hematocrit. At higher
hematocrit levels during ReHuEpo therapy, a plasma volume decrease during
dialysis will induce even more hemoconcentration and consequently increased
blood viscosity compared to lower hematocrit levels. As was published by
London, venous tone was increased in ReHuEpo treated dialysis patients to
maintain venous return [22], A decrease of venous return will lead to a decrease
of left ventricular end diastoiic diameter as a preload parameter and a decrease
of stroke volume.
We investigated at low and high hematocrit plasma volume preservation and
hemodynamic changes during combined ultrafiltration/dialysis with special
attention to left ventricular end diastoiic diameter, being a preload parameter and
to changes in stroke volume.
Patients and methods
Nineteen chronic hemodialysis patients with renal anemia were included in the
study (8 men, 11 women). The mean age was 47 years (27-78 years).
Patients with severe hyperparathyroidism, signs of aluminium intoxication,
diabetes mellitus or cardiac dysfunction, defined as a left ventricular ejection
fraction <40% and/or clinically important valvular disease were excluded. All
patients were normotensive at entrance of the study with or without antihyper-
tensive medication. Five out of 19 patients were using calcium entry blockers
and/or ^-blocking agents. None of them used ACE inhibitors. Vasoactive
medication was temporarily stopped 48 hours before the investigations.
The patients were studied during a standardized midweek 3 hours dialysis
treatment at low hematocrit (before ReHuEpo therapy) and also at a high
hematocrit (during ReHuEpo therapy). The patients were their own controls.
The dialysis treatment consisted of bicarbonate hemodialysis (a hemophane
artificial kidney [GFS plus, Gambro], Kt/v >1, blood flow 250 ml/min, dialysate
flow 500 ml/min). The dialysate composition was: sodium 140 mmol/1, potas-
sium 2.0 mmol/1, calcium 1.75 mmol/1, magnesium 0.5 mmol/1, bicarbonate 34
mmol/1, acetate 3 mmol/1, chloride 107.25 mmol/1. The temperature of the
dialysate was 37°C.
55
The patients were dialyzed to their clinical dry weight. The ultrafiltration
volume was in each patient comparable in the low hematocrit dialysis treatment
and in the high hematocrit dialysis treatment.
The ReHuEpo therapy was administered intravenously, starting at an initial
dose of 150 IU/kg/week, given in a 3 dosages/week schedule. Adjustments of
the dose were carried out monthly, according to the response as defined by an
increase or a decrease of 5% or more as compared to the preceding hematocrit
value. The goal for this study was a hematocrit of >30%. Oral iron supplemen-
tation was given in all patients.
Before and after the two studied hemodialysis treatments (at low and high
hematocrit) in each patient, fluid status was determined using echography of the
inferior caval vein [23]. Before each studied hemodialysis treatment, plasma
volume was measured according to the i'^Albumin method [24]. Red blood cell
volume was calculated from the plasma volume and the hematocrit: RBCV =
PVjn (Hctin/1-Hctjn). Changes of plasma volume during the dialysis treatment
were calculated according to the serial hematocrit method: PVt = RBCV.(1-
Hct/Hct) [25]. The plasma volume preservation (%) is the cumulative fluid
mobilization (VFM) in relation to the total ultrafiltration (VUF): VFM/VUF.
The extracellular fluid mobilization (VFM) was calculated as the difference
between VUF and the change of plasma volume at time t: VFM = VUF-(PVFo-
PVt).
Furthermore, blood samples were taken in ice-chilled tubes before and after
hemodialysis for determination of noradrenaline and adrenaline (HPLC method;
interassay variance <8%), a-ANP (RIA method; interassay variance <12%),
plasma colloid osmotic pressure (COP; Wescor 4400 colloid osmometer), os-
molality (Osm, Wescor 5500 Vapor Pressure Osmometer) and serum albumin
(Alb; BCP, Dimension).
Hemodynamic monitoring consisted of a continuous blood pressure registration
(mean arterial pressure; MAP) during the studied dialysis treatment using a
Dynamap device. Also, before and after the studied dialysis treatments, stroke
volume (SV) was determined by the Duplex doppler method (Hewlett Packard
770020A; 3.5 MegaHerz); stroke index (SI) and cardiac index (CI) were calcu-
lated from SV, heart rate and body surface area [26-27]. Also, left ventricular
end diastolic diameter (EDD) and left ventricular end systolic diameter (ESD)
were determined by echocardiography [28]. The fractional fiber shortening was
calculated according to the formula (EDD-ESD):EDD x 100 (%).
Statistical analysis was done using the paired student t-test for comparison of
pre- and postdialysis results. For comparison of hemodynamic changes during
dialysis at low and high hematocrit, MANOVA was used. Stepwise, multivari-
ate analysis was used to assess relative importance of factors influencing the
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decrease in stroke index during dialysis at high hematocrit. A p-value <0.0S was
regarded as statistical significant.
Results
The mean hematocrit before ReHuEpo therapy was 0.22 ± 0.04 and during
ReHuEpo therapy 0.33 ± 0.04 (p<0.001). Plasma volume before dialysis at the
low hematocrit was 3557.0 ± 804.4 ml and at high hematocrit 3118.9 ± 707.5
ml (p<0.001), and the RBCV was respectively 1015.5 ±217.9 ml and 1576.8 ±
410ml(p<0.001).
The initial hemodynamic parameters before each studied standardized dialysis
treatment at low and high hematocrit were comparable (table 1) except for the
mean arterial pressure. The ultrafiltration volume was comparable in each paired
dialysis treatment at low and high hematocrit (2191 ± 979 and 2451 ± 975 ml
respectively, ns). Cardiovascular medication was not changed in the study
period.
Plasma volume preservation during dialysis at low and at high hematocrit was
comparable (figure 1). The total plasma volume decrease was -282 ± 340 ml at
low hematocrit and -373 ± 377 ml at high hematocrit (ns) (figure 2), and the total
blood volume after dialysis was 4290.5 ml respectively 4322.7 ml (ns). Osmo-
lality decreased from 307.1 ± 13.8 to 291.8 ± 9.7 mosm/kg (p<0.001) at low
hematocrit and from 302.0 ± 8.3 to 287.1 ± 7.6 mosm/kg (p<0.001) at high
hematocrit. Osmolality after hemodialysis at high hematocrit was lower than
osmolality at low hematocrit, although not significantly (p=0.08) (figure 3).
Oncotic pressure during dialysis did not increase significantly from 3.5 ± 0.4
to 3.7 ± 0.5 kPa at low hematocrit, but increased significantly from 3.2 ± 0.3 to
3.8 ± 0.7 kPa (p<0.01) at high hematocrit. The increase of oncotic pressure was
significantly higher during hemodialysis at high hematocrit (0.6 ± 0.6) com-
pared to the increase of oncotic pressure at the low hematocrit (0.2 ± 0.5)
(p<0.02).
Plasma albumin levels during dialysis did not increase significantly (from
31.1 ± 2.8 to 31.9 ± 3.0 g/1) at low hematocrit, but increased significantly (from
29.7 ± 2.7 to 31.7 ± 3.9 g/1, p<0.01) at high hematocrit. The increase of albumin
levels was significantly higher during dialysis at high hematocrit (2.0 ± 2.9 g/1)
compared to the increase of albumin at the low hematocrit (0.8 ± 2.8 g/1)
During the studied standardized dialysis treatments, EDD and ESD decreased
significantly as did body weight and VCD in both paired dialysis treatments at
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Table 1: Hemodynamic parameters before and after dialysis at low (uncorrected) and high
(corrected) hematocrit (Ht).
(VCDI = indexed cavai vein diameter determined echocardiographically)
LowHt High Ht
Before After Before After
EDDffiffl
ESD mm
SI
50.4 ±5.5 (0.01) 48.5 ±6.8 50.4 ±5.2 (0.001) 46.9 ±7.1
33.4±5.5 (0.02) 31.8±6.3 34.3±6.2 (0.001) 31.2±7.5
4.01 ±0.8 3.8 ±0.5 3.9 ±0.6 (0.01) 3.3 ±0.6
54.1 ±10.0 49.7 ±8.8 55.1 ± 9.9 (0.001) 42.1 ± 11.6
HR Wmi« 75 ± 8 78 ± 11 72 ± 9 (0.02) 83 ± 14
VCDImm/m* 10.2 ±3.3 (0.001) 8.7 ± 3.2 10.2 ±2.7 (0.001) 8.3 + 2.6
Weight *g 67.2 ±9.8 (0.001) 65.3 ±9.4 67.4 ±10.5 (0.001) 65.2 ± 10.3
MAP mmtfg 94.9 ±10.8 91.8 ± 12.6 102.5 ± 14.7 (0.05) 96.8 ±16.7
Adrenaline ngW 0.90 ±0.90 (0.01) 0.45 ± 0.43 1.02 ± 0.62 (0.001) 0.62 ±0.40
Noradrenaline ng/m/ 3.36 ±1.74 2.68 ± 1.3 3.14± 1.61 3.01 ±1.71
low and high hematocrit. The decrease of CI, SI and MAP, and the increase of
heart rate (HR) was only significant during the dialysis treatment at high
hematocrit (table 1). Fractional fiber shortening was comparable at low and high
hematocrit: predialysis 33.9 ± 4.4% and postdialysis 34.6 ± 5.7% at low hema-
tocrit and predialysis 32.3 ±6.1% and postdialysis 34.6 ± 6.9% at high hemato-
crit (ns). Adrenaline decreased significantly during dialysis and also
noradrenaline decreased, although not statistically significant. a-ANP de-
creased to the same extent in both dialysis treatments at low and at high
hematocrit (from 229.2 ± 99 to 140.0 ± 87, p<0.001; and from 229.6 ± 94.9 to
147.8 ± 97 pg/ml, p<0.001; respectively).
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Figure 1: Plasma volume preservation at low and high hematocrit (before and after ReHuEpo)
during a standardized bicarbonate dialysis.
VFM/VUF = fluid mobilization divided by ultrafiltration volume x 100%
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Figure 2: Changes in plasma volume at low and high hematocrit during a standardized
bicarbonate dialysis.
Table 2: Comparison of hemodynamic parameters at low and high hematocrit (Ht) before
and after dialysis.
Before After
LowHt High Ht Low Ht High Ht
CL
SI m///>/m2
HR fr/min
VCDI mm/m^
Weight **
MAP mffi/Zj
Adrenaline «g/m/
Noradrenaline
4.01 ±0.8
54.1 ± 10.0
75 ± 8
10.2 ±3.3
67.2 ± 9.8
3.9 ±0.6 3.8 ±0.5 (0.01) 3.3 ±0.6
55.1 ± 9.9 49.7 ±8.8 (0.02) 42.1 ± 11.6
72 ±9
10.2 ± 2.7
78 ± 11
8.7 ± 3.2
67.4 ±10.5 65.3 ±9.5
94.9 ±10.8 0.05 102.5 ±14.7 91.8 ±12.6
0.89 ±0.90 1.02 ±0.62 0.45 ±0.43
3.36 ± 1.74 3.14 ± 1.61 2.68 ± 1.31
83 ±14
8.3 ±2.6
65.2 ± 10.3
96.8 ±16.7
0.62 ± 0.40
3.01 ±1.71
VCDI = indexed caval vein diameter determined echocardiographically
There was a significant difference in SI and CI, but not in HR after dialysis
at low compared to high hematocrit (table 2). Furthermore, MAP before dialysis
was significantly higher at high hematocrit compared to low hematocrit (table
2). Comparing the changes during dialysis at low and at high hematocrit of the
different parameters revealed a significant difference for ASI during dialysis at
low hematocrit (ASI -4.3 ± 9.4 ml/b/m^) compared to the values at high
hematocrit (ASI -12.9 ±11.4 ml/b/m*, p<0.01), and a significant difference for
AHR during dialysis at low hematocrit (AHR +3.0 ± 9.0 b/min) compared to the
values at high hematocrit (AHR +10.3 ± 13.0 b/min, p<0.02). The decrease in
EDD tended to be higher at high hematocrit (-3.5 ± 3.5 mm) compared to values
at low hematocrit (-1.8 ± 2.5 mm, p=0.07).
Studying at high hematocrit ASI after hemodialysis as dependent variable, and
hematocrit after hemodialysis, end diastolic diameter after hemodialysis and
ABV as predictive variables in multiregression analysis revealed a significant
multiple r (r=0.64, p<0.01) for EDD only.
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Figure 3: Osmolaiity (Osm) and colloid oncotic pressure (COP) before and after hemodialysis
at low (before ReHuEpo) and high (after ReHuEpo) hematocrit.
Discussion
Erythropoietin (ReHuEpo) therapy leads to an increase of red blood cell volume
with a concomittant decrease of plasma volume, while total blood volume
remains constant [19]. The removal of the same amount of fluid by ultrafiltration
at a higher hematocrit level with a lower initial plasma volume would lead to a
relative higher increase of colloid oncotic pressure during dialysis compared to
dialysis at a lower hematocrit. Moreover, the decreased plasma volume at higher
hematocrit levels will decrease the plasma flow through the artificial kidney at
the same blood flow, which could influence the decrease of osmolaiity. Both
colloid oncotic pressure [10-11] and osmolaiity [12-18] are important factors in
determining plasma volume preservation during dialysis.
In the present study, plasma volume preservation was identical in the same
patients at low and high hematocrit levels. Although the increase in colloid
oncotic pressure was significantly higher at high hematocrit levels, there was a
tendence to lower osmolaiity levels after dialysis at higher hematocrit levels. An
increase of colloid oncotic pressure will improve plasma volume preservation
by inducing a fluid shift from the interstitial to intravascular pool, whereas a
greater fall in osmolaiity will deteriorate plasma volume preservation because
of a shift of fluid from intravascular/interstitial to the intracellular pool. The
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explanation for the observed difference between the higher percentage of in-
crease in colloid osmotic pressure as compared to the percentage of increase in
serum albumin levels during dialysis, at low as well as at high hematocrit, could
be related to the Donnan effect.
The same ultrafiltration volume with the same decrease of blood volume at
low and high hematocrit, as could also be concluded from comparable decreases
in a-ANP, during a standardized dialysis treatment revealed a significant de-
crease of mean arterial pressure and stroke index at high hematocrit, while at a
low hematocrit no significant hemodynamic changes could be measured. This
could be explained by differences in left ventricular contractility or by changes
in preload due to a different distribution of blood volume.
The dialysis protocol was the same at low and high hematocrit with regard to
the buffer concentration, calcium concentration and the used dialyzer, resulting
in comparable changes of ionized calcium and acid-base status, factors known
to be involved in cardiac contractility. Furthermore, no differences could be
found in the levels of adrenaline and noradrenaline after dialysis at low and high
hematocrit.
Indeed, in this study fractional fiber shortening as a parameter of left ventri-
cular contractility was not significantly different at low and high hematocrit.
The left ventricular end diastolic diameter as a preload parameter decreased
significantly during both paired dialysis treatments. Although not significantly,
the decrease in left ventricular end diastolic diameter tended to be higher at high
hematocrit. In multiregression analysis, studying the decrease of stroke index at
high hematocrit as dependent variable and hematocrit postdialysis, left ven-
tricular end diastolic diameter postdialysis and Ablood volume as predictive
variables revealed a significant relation of Astroke index with the left ventricular
end diastolic diameter postdialysis. This indicates that a decreased preload at
high hematocrit levels played a role in the decrease of stroke index. However,
the blood volume changes were comparable at low and high hematocrit. This
can only be explained by a decrease of venous return due to differences in
distribution of blood volume. Venous return is dependent on an increase of
peripheral vascular resistance, inducing a passive venoconstriction, which is
only a temporary effect. A continuous increased peripheral vascular resistance,
however, will reduce venous return. Venous return is also dependent on active
venoconstriction and on the venous resistance. Peripheral vascular resistance is
known to be increased continuously during ReHuEpo therapy, resulting in a
negative effect on venous return, whereas venous tone was shown to be in-
creased which would improve venous return [22]. Increased blood viscosity
during ReHuEpo therapy would decrease venous return by an increased venous
resistance [20]. In an animal experimental study of Murray et al, mean cardiac
output was plotted against mean hematocrit ratios obtained during control
periods and after isovolemic exchange with dextran solutions of three different
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molecular weights. Recipients of low molecular weight dextran had higher
cardiac outputs at comparable hematocrits [29]. In the present study, we could
not find at high hematocrit a relation between postdialysis hematocrit, one of the
factors determining blood viscosity, and the postdialysis left ventricular end
diastolic diameter and stroke index, which does not rule out an effect of total
blood viscosity. So, it seems that the causes of the intradialytic hemodynamic
changes at high hematocrit levels are multifactorial. For clinical practice we
have to realize that hypovolemia after hemodialysis will exaggerate all the
factors which are possibly involved in the intradialytic hemodynamic changes
at high hematocrit, as there are peripheral vascular resistance and blood viscos-
ity with an increased risk of hemodynamic instability, especially in patients with
a compromised cardiac function.
In conclusion, plasma volume preservation during dialysis at low and high
hematocrit levels is the same, although on basis of different changes in colloid
oncotic pressure and osmolality. At higher hematocrit levels, stroke index
decreased significantly and was related to the decrease of left ventricular end
diastolic diameter, a preload parameter, although blood volume changes were
comparable. This might indicate a decreased venous return.
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Abstract
Erythropoietin (ReHuEpo) treatment may lead to an increased incidence of
fistula thrombosis, probably related to changes in blood viscosity, hemostasis,
hemodynamics, and actual fluid status. In 10 normovolemic hemodialysis pa-
tients, we studied the relative contribution of each factor on Cimino fistula flow
during ReHuEpo therapy. We used Duplex scanning to detect fistula stenosis
and Brachial Artery Spectral Analysis to measure fistula flow. At higher hema-
tocrit (22 ± 3 -> 37 ± 3%, p<0.001) (achieved in 8.0 ± 3 months) grade of
stenosis at anastomotic level as well as at different levels in the efferent cephalic
vein was unchanged. The diastolic as well as the systolic frequency in the
brachial artery decreased, indicating decreased flow. Blood viscosity (BV;
230S"') increased. Cardiac index (CI) decreased whereas mean arterial pressure
(MAP) was unchanged. Multiregression analysis only disclosed a significant
correlation between ACI-Asystolic flow (r=0.74, p<0.02) and AMAP-Adiastolic
flow (r=-0.71, p<0.05) in the brachial artery.
Introduction
Dialysis fistula function is of utmost importance to assure an efficient dialysis
treatment. Dialysis fistula occlusion will include many problems, both for the
patient as well as for the treating physician. Dialysis fistula failure, in the period
before treatment with recombinant human erythropoietin (ReHuEpo), was
mainly related to progressive anatomical lesions.
Since thrombosis of the fistula is usually caused by venous stasis associated
with progressive stenotic lesions at the anastomotic level, but also in the efferent
vein due to intimal hyperplasia [1], preexistent anatomical factors like the
amount and degree of venous stenosis and peripheral arterial disease determine
the outcome of fistula formation [2], Schwab et al reported that increased venous
extracorporeal pressures of > 150 mmHg, when untreated, lead to an increased
incidence of fistula thrombosis when compared to those whose stenotic lesions
had been treated by percutaneous transluminal angioplasty [3].
Reilly et al [4] compared in a retrospective study patients on maintenance
dialysis, not treated with ReHuEpo, with and without fistula thrombosis, and
found a higher extent of platelet aggregation, a lower threshold response to ADP,
a higher beta-thromboglobulin level, and a higher whole blood viscosity at low
shear rate in thrombotic patients. Multivariate regression analysis in a prospec-
tive study by the same authors to the patency of newly constructed AV-fistulas
disclosed that the preoperative platelet counts, beta-thromboglobulin level, and
plasma viscosity were the best predictors for fistula thrombosis during a follow-
up of 1-18 months.
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Treatment with ReHuEpo has been reported to lead to an increased incidence
of dialysis fistula thrombosis. Factors like increased blood viscosity, prothrom-
botic changes in platelet function and other hemostatic and fibrinolytic par-
ameters, and the observed decrease in cardiac output all might contribute. In
addition, the female sex [5], diabetes mellitus {6], and hypovolemia could imply
a greater risk on flow related complications during treatment with ReHuEpo.
The presence of anatomic fistula lesions together with the above mentioned
ReHuEpo related factors could lead to fistula flow changes, predisposing to
fistula thrombosis.
The aim of our prospective study was to determine the influence of potential
risk factors for shunt thrombosis during treatment with ReHuEpo on fistula
flow.
Patients and methods
Ten chronic anemic (hematocrit = Ht < 25%) patients (6 female, 4 male) with a
Brescia/Cimino fistula were selected. The mean age of the group was 54 ± 16
(27-80 years). Patients with cardiac dysfunction (defined as left ventricular
ejection fraction < 40%), with diabetes mellitus, aluminium intoxication, and
severe hypertension (p diast > 100 mmHg) were excluded from the study.
The patients were treated with ReHuEpo (Eprex, Cilag, Belgium), adminis-
tered intravenously after every dialysis according to the so called low and slow
dose schedule. The dose was adjusted monthly, depending on the response and
aiming at a target Ht of ± 35%.
Five of the patients did not use antihypertensive and/or cardiovascular drugs.
The other patients were treated with calcium entry blockers (Nifedipine Retard).
The actual fluid status of the patient was determined by serial assessment of
the inferior caval vein diameter and collapsibility index by means of echo-
graphy, and dry weight adjusted according to the inferior caval vein parameters
of normovolemia [7].
All investigations were performed 20-24 h after dialysis, the moment of most
optimal plasma volume preservation [8]. The investigations were done before
treatment with ReHuEpo and after reaching the target Ht of ± 35% whereby each
patient served at his own control.
Fistula function
The examination of the Brescia/Cimino AV-fistula was performed by duplex
scanning and spectral analysis with an ATL Ultramar IV Duplex scanner. These
examinations were done with the patient in the supine position after a period of
69
10 min of rest. A 10 mHz B-mode sector transducer was used for the localization
and detection of arteries and veins and for a constant 60° angle of insonation
with respect to the vessel axis. A 5 mHz pulsed Doppler beam was used to
perform quantitative spectral analysis.
Diagnosis of fistula stenosis, which might interfere with our interpretation of
the effect of ReHuEpo on fistula flow, was performed by the determination of
the maximal frequency shift (MFS) in the Doppler spectrum at the anastomotic
level, and the peak systolic frequencies (PSF) at the proximal cephalic vein (± 2
cm proximal of the anastomosis; PV), but also at the distal level (DV) of the
efferent vein in the upper arm. The coefficient of variation was less than 5%.
In addition, the blood pressure in the thumb at the fistula side (TP), also an
indicator of especially the AV-anastomotic patency and flow, was measured in
the supine patient after a period of 15 min of rest. Systolic thumb pressure was
determined by slowly deflating a 20 mm wide cuff around the base of the thumb,
inflated to a suprasystolic level while the first inflow was recorded with a
photoplethysmographic cell, used as a pulse sensor (Medasonic Vasculab).
Thumb pressure was measured with open fistula and during digital compression
of the efferent vein. A low pressure at open fistula and an increase of > 25 mmHg
after compression was considered to represent a valid fistula function. Further-
more, the thumb-to-brachial artery blood pressure index (T/B index) with open
(O) respectively compressed (C) fistula was calculated as an additional par-
ameter for the anastomotic patency [2].
Indirect duplex ultrasound scanning measurements of the fistula function,
recording the afferent fistula flow, were performed by brachial artery (a) spectral
analysis. The absence or presence of diastolic flow (DFa = diastolic flow with
open fistula - diastolic flow during efferent vein compression) and the magni-
tude peak systolic flow (PsFa = systolic flow at open fistula) is indicative for
fistula flow.
The duplex ultrasound scanning method as described is a noninvasive method
reported to possess high diagnostic accuracy when digital substraction angio-
graphy was used as the golden standard. Especially when the peak systolic
frequency was used as parameter and the cut-off value of 12 and 8 kHz for the
anastomotic level respectively the efferent vein were accepted, the predictive
value of this method for significant stenosis was rather high: a positive predic-
tive value and a negative predictive value of 86%, 76% and 82%, 99% for the
detection of anastomotic stenoses and stenoses in the efferent vein respectively
[9].
All fistulas were functioning clinically satisfactorily as represented by an
adequate flow for dialysis (>250 ml/min) before the start of the study. Venous
pressure (VP) in the extracorporeal circuit, an indicator of efferent venous fistula
flow, was recorded during dialysis by the venous pressure monitor of a Gambro
AK-100 hemodialysis machine, at an extracorporeal blood flow of 250-300
ml/min, through 16 gauge needles. Of 3 consecutive dialysis treatments, before
and after treatment with ReHuEpo, the data were averaged to cope with the
variability in venous pressures caused by needle placement. Under these condi-
tions, venous dialysis pressures >150 mmHg were considered abnormal and to
represent significant obstruction according to Schwab et al. [3J.
Macrocirculatory indices
Card/ac zVufct am/ mean arreria/ pressure
Stroke volume was calculated from the cross-sectional area of the aortic valve
and the maximal integral flow velocity in the ascending aorta, both assessed in
the early systole of the cardiac cycle, with the use of a Hewlett-Packard
(770-20A) 3.5 mHz Duplex scanner. From these variables, the cardiac index
(CI) (L/minW) was calculated [10]. The inter- and intraobserver variability of
this method has been reported to be less than 10% [1].
Mean arterial pressure (MAP) (mmHg) was recorded during a 1-h period of
rest with the patient in the sitting position by means of the Penaz method
(Finapress, BP-monitor Ohmeda 2300) at the contralateral arm without fistula
[12].
need
During the dialysis sessions, the administered dose of heparin (U/h), needed to
avoid clotting in the extracorporeal system, was registered before treatment with
ReHuEpo and after the target Ht had been reached. Usually, dosages were
increased at the moment of observed clotting in the venous bubble trap and in
the fibers of the artificial kidney with steps of 250 U maintenance dose/h of
dialysis.
/?neo/og/c parame
Whole blood viscosity (BV) was determined using a Wells-Brookfleld micro-
viscosimeter (model LVT-C/P); 2 ml of heparinized fresh whole blood was
immediately handled at shearrates (SR) of 230S' and 11.50S"', respectively, at
a constant temperature of the jacketed sample cup of 37°C. From the scale, the
shear stress (SS; dyne/cm^), created by the rotating spindle in the blood filled
71
sample cup, could be registered. The actual BV subsequently could be calculated
from the formula:
„ . , , , 55*100B V ( c p s ) = — ^ —
The accuracy of this system has been reported to be within 1 % of whatever range
is employed. Sensitivity and reproducibility is within 0.2%.
Red blood cell aggregation (Eaggr) was determined with an automatic aggre-
gometer (Myrenne): one droplet of heparinized fresh blood was immediately
sheared at 3 S"', and the result could be read on the digital screen [ 13]. Red blood
cell deformability (Eflex) was examined by ektacytometry [14] and expressed
in the so called elongation index after resuspension in a solution of phosphate
buffer (1:400) with a high molecular polymer, resulting in a high osmolar
suspension (600 mosmol/kg).
Laboratory
Ht and the amount of platelets (PC) were determined weekly with routine
laboratory methods. Skin bleeding time (BT) as an indicator of the primary
hemostatic function was evaluated according to the Ivy method and expressed
in min/s.
For the statistical analysis, we used the student's t-test for paired data. A p value
of £0.05 was considered as significant.
Results
During treatment with ReHuEpo, the Ht increased significantly during the
follow-up period of 8.0 ± 3 months from 0.22 ± 0.3 to 0.37 ± 0.3 (p<0.001). The
data on fistula function are depicted in table 1. The MFS at the anastomosis did
not change as did PV as well as DV. Also ATP did not change during the course
of treatment as did the T/B (O) and T/B (C) index.
DFa, at brachial artery level, decreased significantly whereas in the PSFa a
nonsignificant decrease was observed. VP during dialysis showed a significant
increase at unchanged blood flow rates. However, the observed changes were
within the upper limit for significant stenosis. CI decreased significantly (table
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NS
NS
NS
NS
=0.08
NS
<0.01
0.07
<0.025
<0.05
NS
13.5 ±4
4.7 ±4.3
1.9 ±0.3
52 ±26
0.64 ± 0.24
1.04±0.18
1.8 ±0.4
4.2 ±0.8
72 ±18
3.5 ±0.5
100±9
Table 1: Parameters of fistula function and hemodynamic parameters before and after
starting ReHuEpo treatment at a Ht level of ± 0.37
Pretreatment P Posttreatment
8.0 ± 3 months
MFS(kHz) 13.6 ±4
PV (kHz) 6.5 ± 3.5
DV (kHz) 2.3 ± 0.7
ATP(mmHg) 41 ± 15
T/B (O) 0.77 ± 0.24
T/B(C) 1.06 ±0.23
DFa (kHz) 2.6 ± 0.6
PSFa (kHz) 4.7 ± 0.7
VP (mmHg) 53 ± 20
Cl (L/min/m*) 4.0 ± 0.6
MAP (mmHg) 97 ±12
1). MAP did not change throughout the study, and in none of the patients did
antihypertensive medication have to be started or adjusted (table 1).
The administered maintenance dose of heparin (HN) during dialysis had to
be increased throughout the period of treatment from 250 ± 288 to 375 ± 212
U/h (p<0.05).
The rheologica data are presented in table 2. BV increased significantly at
both share rates of 230 and 11.50S"', respectively. Eaggr also showed a signifi-
cant increase. Eflex, as expressed in the elongation index (%), did not change at
both shear rates of 106 and 1350S"', respectively. PC did not significantly
increase whereas the BT shortened (table 3).
Multiregression analysis with the changes in fistula flow parameters (DFa,
PSFa) as dependent variables, and ACI, AMAP, Ht, rheologic parameters and
platelet count as predictive variables, revealed a significant predictive value of
ACI on APSFa (multiple r 0.74, p<0.02) and a significant negative predictive
value of AMAP on ADFa (multiple r -0.71, p<0.05). All other variables did not
reach significance. BV at a shear rate 230S"' was related to ACI although not
significantly (r=0.52, p=0.07).
Table 2: Rheologic parameters before and after starting ReHuEpo treatment at a Ht level of
0.37
Pretreatment P Posttreatment
8.0 ± 3 months
BV (cps)
11.5S-' 2.7 ±1.0 <0.01 3.3 ±1.3
230S' 3.5 ±0.4 <0.02 4.8 ±1.0
Eaggr 5.5 ±3.1 <0.01 6.7 ± 3.4
Eflex (%)
106S' 26 ± 8 NS 27 ± 8
(n= 18-31%)
1.35OS' 58 ±7 NS 59 ± 6
(n=56-68%)
Table 3: Hemostatic parameters before and after starting ReHuEpo treatment at a Ht level of
0.37
Pretreatment P Posttreatment
8.0 ± 3 months
Pc(10'/L) 194 ±71 NS 211±67
BT(min/s) 4 min 14 s ± 1 min 20 s =0.05 3 min 26 s± 1 min 13 s
Discussion
The most common cause of late fistula failure is thrombosis [5], due to a stenosis
in the proximal vein at or just above the anastomosis. Intimal hyperplasia from
turbulent flow or repeated punctures [15] are considered to be etiologic factors.
However, blood flow problems during dialysis will occur only in case of severe
stenosis (>90%). Progressive vascular sclerosis is responsible for diminution of
blood flow and subsequent occlusion by thrombosis. The incidence of throm-
botic occlusion can be further enhanced by treatment with ReHuEpo. Despite
conflicting data, dialysis fistula thrombosis has been reported to occur in an
increased frequency during treatment with ReHuEpo [16, 17].
There are circumstances, which might increase the risk on fistula thrombosis
during ReHuEpo treatment: the progressive and natural course of especially
anastomotic and efferent vein stenoses [1], or a decrease of afferent and/or
efferent fistula flow. The latter could be due to macrocirculatory changes [18,
19], changes in rheology [20] and/or hemostatic changes induced by ReHuEpo
therapy [21, 22], or due to a combination of these factors.
In this study we did not observe changes in the maximal frequency shift at
anastomotic level and the peak systolic frequencies at the different levels in the
efferent vein of the fistula before treatment with ReHuEpo and after reaching
the target Ht, indicating that no significant stenosis developed during the follow-
up period. The thumb pressure measurements, as an indirect representation of
especially the anastomotic patency, confirmed this observation. Furthermore,
we did not experience any hindrance in the arterial inlet flow during dialysis.
Blood flow rates of at least 250 ml/min could be maintained in the follow-up
period. The small but significant increase of extracorporal venous pressures at
constant blood flow rates of 250-300 ml/min during dialysis would indicate
venous stenoses. However, the absolute venous pressure values were still below
the upper limit (150 mmHg) of significant stenosis as indicated by Schwab et al.
[3].
At brachial artery level, the diastolic as well as the peak systolic flow
decreased, indicating a decrease in afferent fistula flow. MacDougall et al. did
not find any decrease in fistula flow by means of Doppler examinations of the
fistula during treatment with ReHuEpo. However, in their study important
methodologie information is lacking. The measured parameters and also the
exact time of the investigations in relation to dialysis are not given, nor did they
consider the actual fluid status of the patient, known to interfere with flow data
at the moment of investigation [23].
Concerning the factors which might induce a decreased fistula flow, a
progression of anatomical lesions in our study could already be excluded. The
evaluation of the macrocirculation disclosed a stable blood pressure during
treatment with ReHuEpo, and normovolemia was maintained. However, cardiac
output decreased significantly and could induce a diminution in fistula flow.
According to the observation of other authors, the actual blood viscosity
increased [20], as did the erythrocyte aggregation, and both could also nega-
tively influence dialysis fistula flow. In our study we did not observe changes in
red blood cell flexibility as indicated by the elongation index, and all values were
within the normal range to the corresponding shear rate. Some studies, however,
reported an improvement of the red blood cell deformability during treatment
with ReHuEpo in hemodialysis patients, probably due to a normalization in the
composition and/or functional restoration of the red cell membrane [24]. The-
oretically, one might expect that in the macrovessels of the dialysis fistula, the
red blood cell deformability should play a minor role.
Concerning the hemostatic parameters in this study, only the platelet count
and skin bleeding time were measured. The platelet count was not different, and
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the skin bleeding time improved in our patients. In an earlier study, we investi-
gated the hemostatic and fibrinolytic system more extensively, and next to an
improvement in bleeding time, we observed that treatment with ReHuEpo
included an increase in in vitro platelet aggregation by way of a lower ADP
threshold, a decrease in protein-C and -S (total and free) antigen levels, and a
decrease in protein-C activity. Furthermore, increased plasminogen activator
inhibitor (PAI) activity levels in patients with fistula thrombosis compared to
patients without thrombosis were observed [21].
Multiregression analysis with changes of fistula flow (DFa, PSFa) as depend-
ent variables and ACI, AMAP, Ht, rheologic parameters and platelet count as
predictive variables, only revealed a significant effect of the change in cardiac
index on the APSFa whereas AMAP had a significant negative predictive effect
on ADFa. The decrease in CI is related to the increase of blood viscosity at high
shear rates but is also due to a decrease in pulse rate as well as stroke index as
was pointed out in earlier reports [18, 19, 25]. The negative correlation of a
decrease of diastolic fistula flow ADFa and the increase of blood pressure is
related to the increase of systemic vascular resistance during ReHuEpo therapy
[18].
In conclusion, during treatment with ReHuEpo fistula flow decreases. The
decrease in CI, which is inversely related to blood viscosity, seems to be a major
determining factor. Fistula thrombosis during ReHuEpo therapy, however, is of
multifactorial origin: anatomical lesions in the fistula in combination with a
decrease of fistula flow, the prothrombotic changes, and the underestimation of
dialysis dry weight during treatment with ReHuEpo all may contribute.
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Abstract
Thromboembolism might complicate the treatment of patients with chronic
renal failure with Recombinant Human Erythropoietin (ReHuEpo). In order to
detect prothrombotic changes, a number of hemostatic and fibrinolytic para-
meters was determined during ReHuEpo treatment of fifteen chronic hemo-
dialysis patients (mean age 47.1 years; ten females, five males). To avoid the
influence of hemoconcentration and/or dilution, the patients were kept normo-
volemic, using the method of echography of the inferior vena cava diameter. In
a first group of eight patients, we investigated platelet count and function.
During ReHuEpo, a significant rise of hematocrit (19 ± 3 to 34 ± 5%; p<0.001)
was observed. Bleeding time shortened (7'33" ± 3'39" to 3'41" ± 3'19";
p<0.001) and platelet count increased (222 ± 45 to 254 ± 49 lO'/l; p<0.005). The
initial negative in vitro spontaneous platelet reactivity became positive in two of
them, whereas the decrease in ADP threshold in the whole group (2.0 ± 0.1 to
1.0 ± 0.4 nmol; p<0.02) indicated an increased induced platelet reactivity. In all
patients prothrombotic changes were observed. The protein-C antigen and
protein-C activity and the total and free protein-S antigen decreased signifi-
cantly. The plasminogen activator inhibitor (PAI) activity in the whole group did
not change significantly (6.4 ± 4.1 to 5.4 ± 4.8 AU/ml). However, in the patients
with fistula thrombosis (n=3), higher values in all test points were found
compared to those without thrombosis.
Introduction
One of the major breakthroughs of the last decade in the treatment of patients
with chronic renal failure is the development of recombinant human ery-
thropoietin (ReHuEpo). ReHuEpo produces a rise in hemoglobin levels and
leads to a significant increase of well being of patients with end-stage renal
disease [1-6]. Unfortunately, ReHuEpo therapy has serious side effects, such as
hypertension. Despite conflicting data it might also predispose to thrombotic
fistula occlusion [7-10], the occurence of which could partly be due to alteration-
s of hemostatic function.
A number of potentially thrombogenic factors has been described. During
ReHuEpo therapy bleeding time as well as the in vitro platelet reactivity
improve. A number of potentially prothrombotic factors has been described,
such as an increased in vitro platelet reactivity, that probably contributes to the
also reported significant shortening of the bleeding time together with the
increased hematocrit [11-21].
Impairment of the fibrinolytic response is associated with a thrombotic
tendency, especially in case of prolonged high levels of plasminogen activator
inhibitor (PAJ) activity [22-27]. Other well-known risk factors include de-
creased levels of the anticoagulant proteins: antithrombin-IH and the protein-C
and -S. The protein-C/S pathway plays a dual role by the inactivation of the
activated coagulation factors V and VIII, leading to a subsequent decrease in
thrombin function, and the proftbrinolytic release of the tissue derived plasmi-
nogen activator and the degradation of PAI type I.
Detailed information about the involvement of the fibrinolytic system in the
occurence of ReHuEpo-related thromboembolism is scarce. An increase in
fibrinogen [15-16], but also a decrease in the plasma levels of protein-C and -S
[28-29], however, have been reported.
The aim of this study was to reinvestigate the changes of platelet function
during ReHuEpo treatment, and to study whether alterations in the fibrinolytic
system may play a role in the thrombogenic complications during ReHuEpo
treatment.
Patients and methods
Two groups of stable chronic hemodialysis patients were studied. None of them
had overt diabetes mellitus and/or high levels of cholesterol or triglycerides and
none was using medication, interfering with hemostasis and/or fibrinolysis.
ReHuEpo (Eprex, Cilag, Belgium) was administered intravenously after
every dialysis, according to the "low and slow" dose schedule, starting at an
initial dose of 50 U/kg with monthly adjustment according to response, aiming
at a target hemoglobin level of 10.5-11.6 g/dl.
To avoid the influence of hemoconcentration and/or hemodilution, all pa-
tients were kept normovolemic adjusting dry weight every two weeks, using the
method of echographic evaluation of the inferior vena cava [30]. Blood samples
were obtained before ReHuEpo treatment and at two intervals when hematocrit
had increased at least 5% compared to the preceding value. The samples were
drawn 20-24 hours after dialysis at 11.30 hours a.m., using a 19 gauge needle
and minimal stasis. Full blood counts were performed in EDTA anticoagulated
blood, using an automatic electronic counter (HI, Technicon) within 2 hours
after sampling. For the study of hemostatic and fibrinolytic parameters blood
was collected in 0.109 M sodium-citrate (9:1). Platelet poor plasma was pre-
pared immediately in a refrigerated centrifuge at 4°C at 2000 x g and stored at
-70°C until assayed. In the first group of eight patients skin bleeding time,
platelet counts and platelet aggregation studies were performed. The second
group consisted of 15 patients, in whom fibrinolytic (PAI activity) and other
hemostatic measurements (AT III, protein-C and -S antigens) were performed.
In the last seven patients of the second group (= group IIB) additional measure-
ments were performed (protein-C activity, tissue plasminogen activator antigen
and plasminogen activity).
The following laboratory methods were used:
1. Platelet function was studied by: 1) bleeding time according to the Ivy
method, and 2) the spontaneous platelet aggregation (SPA) and ADP thres-
hold concentration in fresh citrated platelet rich plasma using a Payton
aggregometer [31].
2. Antithrombin HI activity (%), protein-C activity (%), plasminogen (%) and
PAI activity (%) were all measured in an amidolytic assay (using KABI-kits
AB, Sweden), according to the manufacturers instructions.
3. Protein-C antigen (%) and its cofactor protein-S antigen (%), and the tissue
plasminogen activator antigen (ng/ml) were measured by an enzyme linked
immunosorbent assay (Diagnostica Stago, France).
4. Free protein-S antigen was measured in the supernatant after precipitation of
bound protein-S with PEG 8000.
The coefficient of variation of the amidolytic assays and the antigen determina-
tions with ELISA are 6% and 10% respectively.
Statistics
Student's t-test for paired data and Wilcoxon's nonparametric test for paired
rank data were used for statistical analysis. Next to these a Student's t-test for
unpaired data and a Mann-Whitney test was used for the analysis of PAI activity
(AU/ml) in the patients of group II, for those without and those with dialysis
fistula thrombosis. All data have been analyzed using the SPSS-pc statistical
program, version III. A p-value of <0.05 was considered to be significant. It was
decided that, if non-parametric tests should give different results to those of the
parametric tests as far as the acceptance or rejection of nullhypotheses was
concerned, this had to be reported in the text or in the tables. This was not the
case in our data, so all results are presented as means with standard deviations
and only results of parametric tests are reported.
Results
According to the accepted targets, the moments of reinvestigation were reached
after intervals of 2.2 ± 0.7 months and 3.2 ± 1.0 months respectively. In the
patients of group I hematocrit increased from 19 ± 3 to 34 ± 5% (jxO.001), the
platelet count (PC) increased and bleeding time (BT) shortened. Before treat-
ment with ReHuEpo in vitro spontaneous platelet aggregation occurred in none
of the patients. However, in two of them the in vitro spontaneous platelet
Table 1: Platelet count and bleeding time in group I (n=8) during treatment with ReHuEpo
Pre II III P (Prc-HI)
Hematocrit (%) 19 ±3
Platelet count (x lO'/l) 222 ± 45 ns
Bleeding time (min.sec) 7.33 ± 3.39 •
ADP threshold concentrations 2.0 ± 0.1 •
(normal 1 -4 urn)
27 ±4 • 34 ±5
244151 ns
4.38 ± 1.44 •
0.7 ± 0.4 •
254 ± 49
3.41 ±3.19
1.1 ±0.4
<0.001
<0.005
<0.001
<0.02
»p<0.001;**p<0.05
Table 2: Hemostatic parameters and PAI activity levels in group II during treatment with
ReHuEpo.
Pre II III P (Pre-III)
Hematocrit (%)
Antithrombin III (normal 80-120%)
Protein-C antigen (normal 60-130%)
Total Protein-S antigen (normal 60-130%)
Free Protein-S antigen (normal 30-50%)
Protein-C activity (normal 70-140%)
19 ±3*** 27 ±4***
92 ±13* 85 ±15
114 ±30** 89 ±23
125 ±21** 105 ±21
49 ±11* 43 ±14
33 ±5 <0.001
88 ±13 ns
88 ±16 <0.04
108 ±31 <0.02
42 ± 11 <0.02
121 ±17 108 ±26** 105 ±21 <0.03
PAI activity (normal median value/12 AU/ml) 7 ± 4 7±5 5±5 ns
Between the investigations pre-II and II-III only the significant P-values are presented.
***p<0.001; **p<0.03; *p<0.05
aggregation became positive (during treatment) with an increase in optical
density of 50% after 11 and 15 minutes respectively. The normal ADP threshold
concentration decreased significantly in all patients, indicating an increased
induced platelet reactivity. Although there was a significant increase in the
second treatment interval, the values found were still in the low normal range
and significantly different from the initial treatment value (table 1).
In group II hematocrit increased from 19 ± 3 to 33 ± 4% (p<0.001). The
antithrombin III levels showed a slight but significant transient decrease within
the normal range. In all patients protein-C antigen levels and its cofactor
protein-S antigen (total and free) decreased significantly. Also, protein-C activ-
ity levels decreased significantly. However, all changes occurred within the
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Table 3: Additional fibrinolytic measurements in group IIB (n=7) during treatment with
ReHuEpo
Pre II III P(Pre-III)
TPA antigen (normal 1-12 ng/ml) 4.7 ± 2.3 5.2 ± 3.3 4.8 ± 2.6 ns
Plasminogen activity (normal 70-130%) 98 ± 15 96 ± 13 89 ± 11 <0.04
Table 4: Mean (± SD) PAI activity (AU/ml) in the patients of group II, for those without and
those with dialysis fistula thrombosis.
Pre II III P(Pre-III)
Non-thrombotic(n=12) 6.412.9 6.613.6 3.812.7 <0.03
I I I
ns ns p<0.01 (t-test)
p<0.03 (Mann-Whitney test)
I I I
Thrombotic (n=3) 8.218.0 14.2114.0 12.016.0 ns
normal range. The PAI activity did not alter significantly in the whole group
(table 2).
In group IIB (see table 3) the tissue plasminogen activator (TPA) antigen
remained unaltered in contrast to the plasminogen activity, which decreased
significantly.
There was no significant correlation between protein-C activity and PAI-ac-
tivity (r=-0.16; p=0.72). Also the decrease of protein-C antigen was not signifi-
cantly related to the PAI activity (r=-0.45; p=0.26).
Fistula thrombosis occurred in two patients of group I and three patients of
group II.
table 4 shows that in the non-thrombotic patients of group II PAI activity
levels decreased, while in the thrombotic patients the PAI activity levels tended
to increase and were higher at all test points compared to the non-thrombotic
ones. Using the unpaired Student's t-test, the PAI activity levels of the non-
thrombotic individuals at III were significantly lower than those with shunt
thrombosis (p<0.0l: t-test; p<0.03; Mann-Whitney test).
Discussion
Our observation that during ReHuEpo treatment bleeding time is improving and
the platelet count is increasing, confirms the data of others [11-12, 16, 32]. The
improvement in bleeding time might be caused by an increase of red blood cell
size and mass, both enhancing platelet adhesion by increasing the rate of radial
transport of centrally flowing platelets to the vessel wall [33-35]. The improve-
ment in bleeding time could also be related to the elevation of factor VIII clotting
activity (F V1II:C) as well as the von Willebrand factor antigen (vWF:AG) and
its ristocetin cofactor (vWF:Ricof). all of which are known to participate in the
binding of platelets to the vessel wall [32]. Red blood cell deformability seems
to influence the platelet vessel wall interaction as well, in a less pronounced way
and especially at higher shear rates, with an inversed relationship between
deformability and platelet adherence [36]. Improvements in viscoelastic proper-
ties of the red cell membrane with a subsequent increase in red cell deformability
during ReHuEpo treatment are reported and in consequence might negatively
affect the adhesion stimulating influence of the increased red cell volume and
mass [37].
The increase of in vitro platelet reactivity, spontaneously and after threshold
doses of ADP, is in accordance with the observations made by others [13-20].
This increased platelet aggregation might be due to an increased plasma mem-
brane Na-H antiporter activity [38] and the increase in platelet free calcium
mobilization from the intracellular dense tubular system [11,27]. Subsequently,
platelet aggregation may be evoked by the intracellular release of aggregation-
stimulating constituents, the activation of the arachidonate pathway and media-
tion in the receptor-dependent extrinsic platelet activation [39]. The mechanism
of release of the intracellular platelet calcium by ReHuEpo is greatly unknown,
but analogy might exist with the effects of ReHuEpo on proliferation and
differentiation of more mature erythroid progenitors (CFU-E) and on the pro-
liferation of immature erythroblasts, where the intracellular free Ca^*-concen-
tration is supposed to play a mediating role in the effects of hematopoietic
growth factors [40].
No consensus exists to which extent antithrombin HI levels are influenced by
ReHuEpo therapy. We have found that antithrombin III remained unaltered,
except for a small but significant transient decrease within the normal range. An
increase [16, 32] as well as a decrease of antithrombin III during ReHuEpo have
been reported [41-42]. However, detailed information about study design in
these reports is lacking, so even attempts to explain these inconsistent findings
remain speculative. More consensus exists about the influence of ReHuEpo on
the protein-C and -S system. McDougall et al. observed a significant decrease
of levels of both protein-C and protein-S antigen [28-29]. We found a significant
decrease of both antigens. Because activity levels may be expected to be
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independent to changes in plasma volume during ReHuEpo treatment, protein-C
activity was additionally measured and found to be significantly decreased as
well.
A decrease of protein-C activity theoretically might lead to an increase of the
PAI activity levels and to a decrease in tissue plasminogen activator levels.
Regression analysis, however, between the difference of the PAI activity and
protein-C activity and protein-C antigen levels disclosed no significant relation-
ship.
Regarding the patients who developed thrombotic fistula occlusion, com-
pared with those who did not, no significant differences in the enhanced platelet
function and counts, the increase of the in vitro platelet reactivity as well as other
hemostatic and fibrinolytic parameters, except for the PAI activity levels, were
observed. PAI activity can behave as an acute phase reactant [43]. However, our
observation of increased PAI activity levels in the thrombotic individuals as
compared to the non-thrombotic ones already before the thrombotic complica-
tions were diagnosed, is not in accordance with the phenomenon of an acute
phase reactant. Although, we cannot exclude an already ongoing process of
fistula thrombosis at the moment of observed increased PAI activity levels.
Whether the increased PAI activity levels are causally related to the ReHuEpo
related thrombotic complications, cannot be concluded from these results be-
cause of the small number of patients in this study and the multifactorial origin
of fistula thrombosis.
In conclusion, during treatment with ReHuEpo, changes in the hemostatic as
well as the fibrinolytic system are found, which might contribute to the observed
thrombotic tendency.
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CHAPTER VII
Summary and conclusions
The strong association between chronic renal failure and its characteristic
normochromic, normocytic and hypoproliferative type of anemia has been
recognized already for a long time. A decreased production of the hormone
erythropoietin in relation to the level of anemia and the subsequently limited
feedback response between erythropoiesis and erythropoietin production result-
ing from the loss of viable renal tissue, has been the most widely accepted
mechanism for the decreased marrow stimulation in kidney disease, ultimately
leading to anemia.
The anemia of chronic renal failure patients, especially if maintained on
hemodialysis, contributes to the already decreased quality of life and leads to
considerable morbidity for which until recently only periodic blood transfusions
offered temporarily relief. However, repeated red blood cell transfusions in-
cluded the risks of transmission of transfusion associated infections, iron over-
load, the generation of cytotoxic antibodies and further erythroid suppression.
Since the concept was postulated that red blood cell production could be
influenced by a hormonal factor, ongoing research ultimately lead to the identi-
fication, isolation and purification of the natural hormone erythropoietin, which
finds it main source in the peritubular capillary endothelial cells and interstitial
fibroblasts of the kidney, and is known to exert its erythropoietic effects on
erythroid progenitor populations in the bone marrow after hypoxic stimulation.
The identification and cloning of the human erythropoietin gene and its sub-
sequent transmission in a suitable mammalial vector created the possiblity to
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obtain unlimited amounts of the so called recombinant human erythropoietin
(ReHuEpo) for therapeutic application.
In many clinical trials since then, ReHuEpo proved its efficacy to correct the
disabling anemia in patients with chronic renal failure resulting in improvement
of general well being including cardial and sexual performance, physical exer-
cise capacity and uremic bleeding tendency. Furthermore, it resulted in the
elimination of transfusion dependency and in the reduction of transfusion related
iron overload. However, also side effects of treatment with ReHuEpo have been
encountered of which the clinically most important are: (1) the development
and/or aggravation of hypertension mainly due to the increased blood viscosity
and increased peripheral vascular resistance, and (2) clotting problems in the
extracorporeal hemodialysis system requiring increased heparin dosages during
dialysis, and thrombosis of high risk dialysis fistulae and other vasculature due
to the increased whole blood viscosity, the changed hemostasis, and the de-
creased peripheral circulatory flow.
The increasing hematocrit during ReHuEpo therapy was expected to have
important effects on macrocirculation in chronic hemodialysis patients but even
more on microcirculation due to changes in cardiac output and blood viscosity
in relation to the structural vascular changes in dialysis patients. Furthermore,
an optimal determination of fluid status would be of hemodynamically more
importance at high compared to low hematocrit, because of the changes in
plasma volume / red blood cell volume ratio and the effect of hemoconcentration
at hypovolaemia.
The present study was performed to evaluate the effects of treatment with
ReHuEpo on macrocirculation and skin microcirculation and fluid status in
normotensive chronic hemodialysis patients after short term treatment (reaching
the target hematocrit) and long term treatment (in the maintenance phase of
hematocrit) (chapter I and II).
In chapter III, the effects of high hematocrit (during ReHuEpo therapy) on
plasma volume preservation and fluid handling compared to the effects at low
hematocrit (before ReHuEpo therapy) are evaluated. Furthermore, the effects of
low and high hematocrit on intradialytic hemodynamic parameters are studied.
Chapter IV deals with the effects of ReHuEpo on dialysis fistula function in
relation to the observed changes in viscosity parameters, primary hemostasis
and macrocirculation.
In chapter V the effects of ReHuEpo on indices of hemostasis and fibrinolysis
are studied also in relation to the observed increased frequency of dialysis fistula
thrombosis.
Chapter I
Treatment with ReHuEpo resulted in a significant increase of hematocrit. The
systemic vascular resistance increased and cardiac index decreased signifi-
cantly, the latter due to a significant decrease of stroke index as well as heart
rate, while mean arterial pressure remained unchanged. Red blood cell volume
increased and plasma volume decreased significantly, whereas total blood vol-
ume remained unchanged maintaining normovolemia using the method of
echography of the inferior caval vein. Skin capillary circulation, as measured by
transcutaneous oxymetry, decreased whereas peripheral oxygenatton increased.
The observation of an increased number of pathological capillary loops in the
distal row of the finger nailfold of dialysis patients compared to controls, studied
by intravital videomicroscopy, raised the question whether the pathological
capillaries might be causally involved in the increase of systemic vascular
resistance and the decrease of skin capillary flow, during treatment with Re-
HuEpo and its concomitant increase of blood viscosity.
Chapter II
During long term treatment with ReHuEpo, maintaining the target hematocrit
after the induction phase of treatment, the observed significant changes in
cardiac index, stroke index and systemic vascular resistance after short term
treatment were no longer different from the initial values. Mean arterial pressure
remained unchanged throughout the whole study period as did blood volume.
The significant increase of red blood cell volume and the significant decrease of
plasma volume after short term treatment remained unaltered at long term. Left
ventricular ejection fraction and the fractional fiber shortening did not change
during the whole period of investigation.
The left ventricular end diastolic diameter and volume decreased after short
term treatment and remained significantly decreased at long term, for which a
decreased venous return could be responsible.
The total left ventricular volume, the end systolic diameter and volume, the
end diastolic posterior and interventricular wall thicknesses and left arterial
diameter did not change significantly during the whole study period.
Although left ventricular mass (LVMI) did not change significantly for the
whole group, in 6 out of the 8 evaluated patients the LVMI decreased. A strong
relation between the initial LVMI and the decrease of LVMI after long term
treatment with ReHuEpo could be found.
The observed improvement in peripheral oxygenation, studied by trans-
cutaneous oxymetry at 37° skin electrode heating, after short term treatment
with ReHuEpo did not change at long term. Also the significant impairment in
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skin capillary flow at short term did not change after long term treatment. The
intravital videomicroscopic studies of the finger nail fold capillaries revealed a
significant decrease in the percentage of pathologic tortuous capillaries after
short term but also at long term treatment whereas the total number of capillaries
per videoscreen did not change.
The improvement in configuration of the nail fold capillaries in the absence
of an improved skin microcirculatory flow suggests persisting structural abnor-
malities at the level of the arterioles.
Chapter HI
The influence of the changed red blood cell volume / plasma volume ratio at
higher hematocrit on plasma volume preservation during dialysis is described in
this chapter.
It turned out that plasma volume preservation at high hematocrit was com-
parable with the plasma volume preservation at low hematocrit. Although the
increase of colloid oncotic pressure during dialysis was higher at higher hemat-
ocrit, this did not result in a better plasma volume preservation. There was a
tendency for plasma osmolality to be lower after hemodialysis at higher hema-
tocrit, which could counteract the effect of the higher increase of colloid oncotic
pressure.
Furthermore, in this study intradialytic hemodynamic parameters were stu-
died at low and high hematocrit, because hemoconcentration after dialysis could
influence venous return and stroke index.
The results showed a significant decrease of stroke index after dialysis at high
hematocrit, which was related to the decrease of left ventricular end diastolic
diameter, being a preload parameter. The change in blood volume was com-
parable, indicating that a decrease of venous return could play an important role.
An increase of venous resistance due to increased blood viscosity could be
involved.
Chapter IV
The occurrence of fistula thrombosis during treatment with ReHuEpo is multi-
factorial of origin: changes in blood viscosity, hemostasis, hemodynamics and
fluid status may all contribute especially when pre-existent vascular abnor-
malities like venous stenosis and/or peripheral arterial disease are present.
In chronic hemodialysis patients fistula function parameters and indices of
blood viscosity and primary hemostasis, cardiac index and mean arterial press-
ure were evaluated and interrelated during treatment with ReHuEpo. Hema-
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tocrit, whoie blood viscosity {at high and low shear rates) and red blood cell
aggregation (low shear rate) increased significantly. Cardiac index decreased
significantly whereas mean arterial pressure remained unchanged. Bleeding
time decreased whereas the amount of platelets remained unaltered. Duplex
scanning and spectral analysts of the fistula disclosed a significant reduction in
the diastoiic brachial artery (afferent) flow as well as a non-significant decrease
in the systolic brachial artery flow. No other changes suggestive for progressive
stenotic lesions in the fistula could be traced by direct and/or the indirect thumb
blood pressure measurements at open and compressed fistula. Venous pressure
in the extracorporeal system at unchanged blood flow during dialysis increased
significantly, however, within the normal range.
Multiregression analysis with the changes in fistula flow parameters as
dependent variables revealed a significant predictive value of the change (A) in
cardiac index on the A systolic brachial artery flow and a significant negative
predictive value of mean arterial pressure on the A diastoiic brachial artery flow,
which is related to the increase of systemic vascular resistance during treatment
with ReHuEpo.
Chapter V
In order to detect prothrombotic changes, a number of hemostatic and fibrin-
olytic parameters were determined before and after ReHuEpo therapy in chronic
hemodialysis patients.
In a first group of patients we observed, after hematocrit raised to 34%, a
shortening of the bleeding time and an increase of platelet count. The initial
negative in vitro spontaneous platelet reactivity became positive in a minority
of the patients after reaching the target hematocrit although the ADP treshold
decreased significantly in the whole group, indicating an increased platelet
reactivity after ReHuEpo therapy.
In a second group of patients prothrombotic changes were observed. The
protein-C antigen and protein-C activity and the total and free protein-S antigen,
being anticoagulant proteins, decreased significantly during ReHuEpo therapy.
The plasminogen activator inhibitor (PAI) activity did not change for the
whole group. However, in the patients who developed fistula thrombosis higher
values of PAI in all test points were found compared to those without throm-
bosis.
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Conclusion
Treatment with ReHuEpo corrected the characteristic anemia of chronic renal
failure patients maintained on hemodialysis, and in consequence ameliorated
physical performance due to improved tissue oxygenation.
ReHuEpo also induced important changes in macro- and microcirculation. At
higher levels of hematocrit, cardiac index decreased on basis of a decreased
heart rate and stroke index. The decrease in stroke index was probably related
to a decrease of venous return, as a result of increased blood viscosity. More
important, long term studies revealed a decrease of left ventricular muscle mass.
This indicates that treatment of renal anemia already in the predialysis phase
could improve the cardiovascular state of these patients.
Peripheral vascular resistance increased during ReHuEpo therapy, resulting
in hypertension in some of the treated patients. There was a decrease of maximal
microcirculatory flow after ischaemia, indicating a possible effect of increased
blood viscosity in combination with structural microcirculatory abnormalities.
Although, after 4 months of ReHuEpo therapy the pathological configuration of
the nailfold capillaries in dialysis patients improved, there still was a decreased
maximal circulatory flow after ischemia.
During treatment with ReHuEpo the plasma volume preservation at higher
hematocrit was comparable with the plasma volume preservation at lower
hematocrit before ReHuEpo treatment. Although colloid oncotic pressure in-
crease was higher at high hematocrit, this effect was counteracted by a more
exaggerated decrease of plasma osmolality.
In the intradialytic period the decrease of stroke index was significantly
higher at high hematocrit compared to low hematocrit in the same patients with
the same ultrafiltration volume. This was related to changes in preload, probably
due to a decrease of venous return at higher hematocrits. Hypovolemia after
hemodialysis may induce exaggerated hemoconcentration that may lead to a
decrease of stroke index and hemodynamic instability. The hemoconcentration
at hypovolemia may also lead to an impairment of capillary flow and tissue
perfusion.
Together with the observed prothrombotic alterations in hemostasis and/or
fibrinolysis and especially in the presence of pre-existent anatomic lesions in the
dialysis fistula, hypovolaemia during treatment with ReHuEpo increases the risk
at shunt thrombosis and other thrombotic complications.
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APTER VIII
Samenvatting
De associatie van chronische nierinsuffïciëntie met een normochrome, nor-
mocytaire en hypoproliferatieve anemie is reeds lang bekend. Een verminderde
produktie van het hormoon erythropoietine in relatie tot de graad van bloedar-
moede en het dientengevolge minder effektieve terugkoppelingsproces tussen
erythropoiese en erythropoietineproduktie, wordt in het algemeen als de belang-
rijkste oorzaak gezien voor de verminderde beenmergstimulatie bij patiënten
met nierziekten.
De anemie bij dialysepatiënten is een belangrijke oorzaak van de afgenomen
kwaliteit van leven en van de verminderde inspanningstolerantie, en kan leiden
tot een aanzienlijke morbiditeit. Periodieke bloedtransfusies boden slechts tijde-
lijk soelaas. Deze bloedtransfusies hielden echter ook het risiko in van over-
dracht van infektieziekten, ijzerstapeling, en het ontstaan van cytotoxische
antistoffen.
Sedert het gepostuleerde concept dat de erythropoiese kon worden beïnvloed
door een hormonale faktor, heeft intenstief onderzoek geleid tot de identifikatie,
isolatie en de zuivering van het natuurlijke hormoon erythropoietine, dat wordt
geproduceerd in de peritubulaire capillaire endotheelcellen en de interstitiële
fibroblasten van de nier. Erythropoietine oefent zijn werking uit op de vroege
voorlopercellen van de rode bloedcelreeks in het beenmerg. De produktie van
erythropoietine wordt gestimuleerd door lokale renale hypoxemie.
De identifikatie en vervolgens het clonen van het humane erythropoietine
gen, en de transmissie ervan in een geschikt zoogdier ais vector, maakte het
mogelijk om te beschikken over zeer grote hoeveelheden van het zogenaamde
recombinante humaan erythropoietine (ReHuEpo). Hierdoor kon ReHuEpo ook
worden aangewend voor therapeutische doeleinden.
Sedertdien heeft ReHuEpo in veel klinische studies zijn effektiviteit aange-
toond ten aanzien van de korrektie van de renale anemie. Het korrigeren van de
anemie bij chronische nierinsufficiënte patiënten leidde tot een verbetering van
het algeheel welbevinden, zoals een verbeterde inspanningstolerantie en psychi-
sche alertheid. Daarnaast was er sprake van een afgenomen bloedingsneiging.
Andere voordelen waren de verminderde transfusie-afhankelijkheid en de re-
duktie van de ijzerstapeling, die het gevolg was van de herhaalde bloedtransfu-
sies in het verleden.
Behandeling met ReHuEpo bleek echter ook gepaard te gaan met bijwerkin-
gen, waarvan de belangrijkste voor de kliniek zijn: (1) het onstaan en/of verer-
gering van de hypertensie, (2) verhoogde stollingsneiging in het extracorporele
hemodialysesysteem met als gevolg een verhoogde heparinebehoefte tijdens
dialyse, en (3) verhoogde kans op thrombose van dialysefistels en andere
thrombo-embolische komplikaties.
Als gevolg van de stijging van de hematocriet kon worden verwacht dat de
behandeling met ReHuEpo bij chronische hemodialysepatiënten belangrijke
effekten zou kunnen hebben op de macro- en microcirculatie. Dit als gevolg van
veranderingen van het hartminuutvolume en van de bloedviscositeit in relatie tot
de strukturele vasculaire veranderingen zoals die bij dialysepatiënten worden
gezien.
Bovendien leek een optimale instelling van de vochtstatus c.q. het dialyse-
streefgewicht bij een hoge hematocriet van hemodynamisch groter belang dan
bij een lage hematocriet als gevolg van de veranderingen in de plasmavolume /
rode bloedcelvolume ratio en de effekten van hemoconcentratie tijdens hypovo-
lemie.
In de eerste hoofdstukken van dit proefschrift worden de effekten geëvalueerd
van de behandeling van ReHuEpo op de macrocirculatie, de huid-microcircula-
tie en de vochtstatus in normotensieve chronische hemodialysepatiënten na
korte termijn therapie, waarbij de hematocriet-streefwaarde werd bereikt
(hoofdstuk I) en na lange termijn behandeling, gedurende welke de bereikte
hematocriet werd gehandhaafd (hoofdstuk II).
In hoofdstuk III worden de effekten geëvalueerd van een ReHuEpo geïndu-
ceerde hoge hematocrietwaarde op de plasma volumepreservatie en de vochtsta-
tus tijdens en na dialyse, en vergeleken met de effekten van een lage hematocriet
op deze parameters vóór behandeling met ReHuEpo. Bovendien worden de
effekten van de hoge en lage hematocrietwaarden bestudeerd op de intradialyti-
sche hemodynamische parameters.
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In hoofdstuk IV worden de effekten van een hogere hematocriet als gevolg
van behandeling met ReHuEpo op de dialyseshuntfunktie weergegeven in
relatie tot de waargenomen veranderingen in de viscositeitsparameters, primaire
hemostase en macrocirculatie.
In hoofdstuk V worden de effekten van behandeling met ReHuEpo bestu-
deerd op diverse indices voor hemostase en fibrinolyse, en wordt de relatie met
dialyseshuntthrombose onderzocht.
Hoofdstuk I
Behandeling met ReHuEpo resulteerde in een signiflkante toename van de
hematocriet. De systemisch vasculaire weerstand steeg en het geïndexeerde
haitminuutvolume daalde signifikant als gevolg van een zowel signiflkante
daling van het slagvolume als van de hartfrequentie. De gemiddelde arterièle
bloeddruk bleef onveranderd. Het erythrocytenvolume daalde en het plasmavo-
lume steeg, beiden signifikant, terwijl het totale bloedvolume onveranderd bleef.
Dit onder handhaving van de normovolemie middels de methode van de echo-
grafie van de vena cava inferior.
De capillaire circulatie in de huid na ischemische vasodilatatie, zoals gemeten
middels transcutane oxymetrie, verminderde terwijl de perifere oxygenatie
toenam. Opvallend was dat er bij intravitaalmicroscopie een verhoogd aantal
pathologische distale capillaire lissen in de vingemagelriem van dialysepatiën-
ten werd gevonden in vergelijking met normale kontrolepersonen.
Hoofdstuk II
Gedurende de lange termijn behandeling met ReHuEpo, waarbij de bereikte
hematocriet-streefwaarde werd gehandhaafd, bleken de signiflkante veranderin-
gen in het geïndexeerde haitminuutvolume en slagvolume, en de systemische
vasculaire weerstand van de korte termijn behandeling niet langer te veschillen
met de uitgangswaarden. Zowel de gemiddelde arteriële bloeddruk als het
bloedvolume bleven onveranderd gedurende de hele studieperiode.
De signiflkante toename van het erythrocytenvolume en de signiflkante
afname van het plasmavolume na de korte termijn therapie bleven onveranderd
op lange termijn. De cardiale linker ventrikel ejektiefraktie veranderde niet
gedurende de onderzoeksperiode.
De linker ventrikel eind-diastolische diameter en volume namen signifikant
af na korte termijn behandeling en dit bleef op lange termijn konstant. Dit zou
gerelateerd kunnen zijn aan een verminderde veneuze terugvloed.
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Het totale linker ventrikelvolume, de eind-systolische diameter en -volume,
de eind-diastolische achterwand en interventriculaire wanddikte en de linker
atrium diameter veranderden niet signifikant gedurende de studieperiode.
Hoewel de geïndexeerde linker ventrikel spiermassa (LVM) voor de gehele
groep niet signifikant veranderde, nam hij in zes van de acht geëvalueerde
patiënten af. Er werd een sterke relatie gevonden tussen de initiële LVM index
en de afname van de LVM index na lange termijn behandeling met ReHuEpo.
De waargenomen verbetering in de perifere oxygenatie na korte termijn
behandeling met ReHuEpo, zoals bestudeerd door middel van transcutane
oxymetrie, veranderde niet tijdens de lange termijn studie, zoals ook gold voor
de signifikante afname van de capillaire flow in de huid.
De intravitale videomicroscopische studies van de distale capillairen in de
nagelriem van de vingers toonden een signifikante afname in het percentage
pathologische tortueuze capillairen, zowel na korte termijn als na lange termijn
behandeling met ReHuEpo, terwijl het totaal aantal capillairen per videoveld
niet veranderde. De verbetering in configuratie van de distale capillairen in de
nagelriem, bij afwezigheid van een verbetering van de microcirculatie in de huid
na ischemische vasodilatatie, suggereert dat er persisterende strukturele afwij-
kingen zijn op het niveau van de arteriolen.
Hoofdstuk III
In dit hoofdstuk wordt de invloed van de veranderde erythrocytenvolume /
plasmavolume ratio bij een hoge hematocrietwaarde bestudeerd op de plasma-
volumepreservatie tijdens hemodialyse.
Het bleek dat de plasmavolumepreservatie bij een hoge hematocrietwaarde
vergelijkbaar was met die bij een lage hematocrietwaarde. Hoewel de toename
van de plasma colloïd-osmotische druk tijdens dialyse bij een hoge hematocriet-
waarde hoger was als bij een lage hematocrietwaarden, resulteerde dit niet in een
betere plasma volumepreservatie. Mogelijk dat de iets lagere osmolaliteit na
dialyse bij een hogere hematocriet het effekt van de hogere colloid-osmotische
druk op de plasma volumepreservatie tegenwerkt.
Bovendien werd in deze studie de intradialytische hemodynamiek betudeerd
bij zowel lage als hoge hematocriet.
De resultaten toonden een signifikante afname van het geïndexeerde slagvo-
lume na de dialyse bij hoge hematocrietwaarden, terwijl dit bij lage hematocriet
niet het geval was. De afname van het geïndexeerde slagvolume bij hoge
hematocriet was signifikant gerelateerd aan de afname van de linker ventrikel
eind-diastolische diameter, een parameter voor de cardiale vulling (preload). De
mate van afname van het bloedvolume was bij hoge en lage hematocriet
vergelijkbaar, hetgeen suggereert dat een afname van veneuze terugvloed naar
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het hart hieraan ten grondslag ligt. Een toename van de veneuze weerstand als
gevolg van de verhoogde bloedviscositeit na behandeling met ReHuEpo zou
hiervoor een verklaring kunnen zijn.
Hoofdstuk IV
Het optreden van thrombose van de shunt tijdens behandeling met ReHuEpo
wordt door meerdere faktoren bepaald. Verandering in de bloedviscositeit, de
hemostase, de hemodynamiek en de vochtstatus na therapie met ReHuEpo
spelen hierbij een rol. De primaire risikofaktor, echter, is de aanwezigheid van
preëxistente vasculaire afwijkingen zoals arteriële en veneuze stenosen in de
AV-fistel.
Doorbloedingsparameters van de dialyseshunt, indices van bloedviscositeit,
primaire hemostase, geïndexeerd hartminuutvolume en de gemiddelde arteriële
bloeddruk werden geëvalueerd.
De hematocriet en de totale bloedviscositeit (bij hoge en lage schuifsnelhe-
den) namen signifikant toe. Het geïndexeerde hartminuutvolume nam signifi-
kant af waarbij de gemiddelde arteriële bloeddruk onveranderd bleef. De
bloedingstijd verkortte signifikant, terwijl het aantal plaatjes onveranderd bleef.
Duplex Doppler onderzoek en Spectral Scanning van de dialyseshunt toonde een
signifikante afname in de diastolische flow van de arteria brachialis zowel als
een niet signifikante afname in de systolische flow van de arteria brachialis.
Andere veranderingen, die suggestief zouden kunnen zijn voor progressieve
stenotische lesies in de dialyseshunt, konden middels direkte methodieken en/of
indirekte duim-bloeddrukmetingen bij open en gecomprimeerde dialysefistel
niet worden waargenomen. De veneuze druk in het extracorporele systeem,
tijdens dialyse en bij een konstante bloedflow gemeten, nam signifikant toe
hoewel binnen het normale gebied.
Multiregressie-analyse met de veranderingen in de doorstromingsparameters
van de shunt als afhankelijke variabelen toonde een signifikante prediktieve
waarde van de verandering in het geïndexeerd hartminuutvolume op de Asysto-
lische doorstroming van de arteria brachialis. Tevens was er sprake van een
signifikant negatieve prediktieve waarde van de gemiddelde arteriële bloeddruk
op de Adiastolische doorstroming van de arteria brachialis, hetgeen gerelateerd
is aan de toename van de systemische vasculaire weerstand tijdens behandeling
met ReHuEpo.
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Hoofdstuk V
Teneinde eventuele prothrombotische veranderingen te evalueren, werden bij
chronische hemodialysepatiënten een aantal hemostatische en fibrinolytische
parameters bepaald voor en na behandeling met ReHuEpo.
In een eerste patiëntengroep werd, nadat de streefhematocriet van 34% was
bereikt, een verkorting van de bloedingstijd en een toename van het aantal
bloedplaatjes gezien. De aanvankelijke negatieve in vivo spontane plaatjesreak-
tiviteit werd positief in een minderheid van de patiënten. De afname in de
ADP-drempel echter daalde significant, hetgeen een verhoogde plaatjesreakti-
viteit aangeeft na behandeling met ReHuEpo.
In een tweede groep van patiënten werden tijdens behandeling met ReHuEpo
prothrombotische veranderingen waargenomen. De spiegels van het proteine-C-
antigeen, de proteine-C-aktiviteit en het totale en vrije proteine-S-antigeen, allen
anticoagulante eiwitten, daalden signifikant.
De plasminogeen activator inhibitor (PAI) aktiviteit veranderde niet voor de
hele groep. Echter, in die patiënten, waarbij zich thrombose van de shunt
cffftwiV&e\de, -werden Vij aYie meetpunten hogere PAl-aktïvïteïtswaaróen gevon-
den als bij de patiënten zonder thrombose.
Konklusie
Behandeling met recombinant humaan erythropoietine (ReHuEpo) korrigeert de
anemie van chronische hemodialysepatiënten en verbetert daarmee het lichame-
lijk welzijn als gevolg van de verbeterde perifere weefseloxygenatie. Therapie
met ReHuEpo leidt tevens tot veranderingen in de macro- en microcirculatie en
de vochtstatus. Bij een hogere hematocrietwaarde en een toegenomen bloedvis-
cositeit daalt het geïndexeerde hartminuutvolume op basis van een daling van
de hartfrequentie en van het geïndexeerde slagvolume. Dit laatste is mogelijk
het gevolg van een verminderde veneuze terugstroom naar het hart.
De lange termijn studie met ReHuEpo liet een afname zien van de linker
ventrikelspiermassa, met name bij die patiënten waarbij sprake was van linker
ventrikelhypertrofie. Op grond hiervan zou ReHuEpo-behandeling in de predi-
alyse-fase gunstige effekten kunnen hebben op de cardiovasculaire status.
De verhoogde perifere vasculaire weerstand als gevolg van de ReHuEpo-the-
rapie kan in sommige patiënten leiden tot hypertensie. De oorzaak hiervan is niet
geheel duidelijk, mogelijk dat de toegenomen bloedviscositeit in relatie tot de
strukturele vasculaire afwijkingen hierin een rol speelt.
Tijdens behandeling met ReHuEpo was de plasma volumepreservatie tijdens
dialyse bij een hogere hematocriet niet verschillend van die bij een lage hema-
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tocriet. De tegengestelde effekten van de geobserveerde veranderingen in plas-
ma osmolaliteit en de plasma coiloid-oncotische druk op de vochtverplaatsing
tussen het intra- en extravasculaire compartiment zouden een verklaring kunnen
zijn.
Gezien de effekten van de hoge hematocriet op de intradialytische hemody-
namiek i.e., een afname van het geïndexeerde hartminuutvolume, zou hypovo-
lemie na dialyse in dit geval een versterkte nsikofaktor zijn. Tevens zou ook de
hemoconcentratie, die hierbij zal ontstaan, lokaal aanleiding geven tot een
verminderde weefselperfusie. Het lijkt dus van belang om met name bij hogere
hematocrietwaarden hypovolemie te voorkomen.
In kombinatie met de waargenomen prothrombotische veranderingen in
hemostase en/of fibrinolyse en vooral in aanwezigheid van eerder bestaande
anatomische afwijkingen in de dialyseshunt, verhoogt ondervulling (hypovole-
mie) tijdens behandeling met ReHuEpo het risiko op dialyseshuntthrombose.

NKWOORD
Terugblikkend op de laatste jaren, waarin het verzamelen van onderzoeksgege-
vens en het uitwerken van de resultaten zijn gestalte vond in de vorm van
meerdere abstracts, congresvoordrachten en artikelen, is het vanzelfsprekend
dat mijn dankbare gedachten daarbij mede uitgaan naar die personen zonder
wiens bijdrage de uiteindelijke totstandkoming van dit proefschrift niet mogelijk
was geweest.
Op de eerste plaats denk ik aan alle dialysepatiënten bij wie de vaak belastende
onderzoeken werden verricht en aan wie dit proefschrift dan ook vooral is
opgedragen. Mijn respekt en grote dankbaarheid gaan uit naar het immense
geduld en doorzettingsvermogen waarover zij beschikten bij het ondergaan van
de vele, vaak herhaalde en tijdrovende onderzoeken, waarbij geen beperking
hun motivatie en moreel kon breken om dat af te maken waaraan ze hun
medewerking hadden toegezegd. De meeste patiënten werden betrokken uit de
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Dat mijn prioriteiten noodzakelijkerwijze wel eens anders gesteld werden als
wenselijk in mijn gezin, heeft het voor Ria, Reinier en Fleur niet altijd gemak-
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